Biomarkers of intrauterine hypoxia and perinatal asphyxia, and gestational age as predictors of neonatal outcome by Seikku, Laura
Department of Obstetrics and Gynecology 
University of Helsinki and Helsinki University Hospital 
Finland 
 
 
 
 
BIOMARKERS OF INTRAUTERINE HYPOXIA AND 
PERINATAL ASPHYXIA, AND GESTATIONAL AGE AS 
PREDICTORS OF NEONATAL OUTCOME 
 
 
 
Laura Seikku 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
To be presented, with the permission of the Medical Faculty of the University of Helsinki, 
for public examination, in Lecture Hall 3, Biomedicum Helsinki 1 
on 24th January 2020, at 12 o’clock. 
Helsinki 2020 
 Supervised by 
 Adjunct Professor Vedran Stefanovic 
 Department of Obstetrics and Gynecology 
 University of Helsinki and Helsinki University Hospital, Helsinki, Finland 
 
 Adjunct Professor Leena Rahkonen 
 Department of Obstetrics and Gynecology 
 University of Helsinki and Helsinki University Hospital, Helsinki, Finland 
 
Reviewed by 
 Adjunct Professor Outi Tammela 
 Division of Neonatology, Department of Pediatrics 
 Tampere University Hospital and Tampere University, Finland 
 
 
 Adjunct Professor Pekka Taipale 
 University of Helsinki and Helsinki University Hospital, Helsinki, Finland 
Mehiläinen Länsi-Pohja Oy, Kemi, Finland 
 
Official Opponent 
 
 Adjunct Professor Susanna Timonen 
 Department of Obstetrics and Gynecology 
 Turku University Hospital and Turku University, Finland 
 
 
 
ISBN 978-951-51-5755-3 (paperback) 
ISBN 978-951-51-5756-0 (PDF) 
 
Unigrafia 
Helsinki 2020 
The Faculty of Medicine uses the Urkund system (plagiarism recognition) to examine all 
doctoral dissertations.  
      To my family  
4 
ABSTRACT 
Fetal life occurs in a relatively hypoxic environment. During normal pregnancy, several 
compensatory mechanisms secure fetal oxygenation and wellbeing. In complicated 
pregnancies, however, intrauterine hypoxia predisposes the fetus to growth restriction, 
stillbirth, neurodevelopmental sequelae such as cognitive dysfunction and cerebral palsy 
(CP), and adverse long-term health impacts. Impairment of respiratory gas exchange—during 
either pregnancy or delivery—leads to tissue hypoxia, and, if prolonged, to metabolic 
acidosis and asphyxia. Worldwide, such asphyxia, diagnosed at birth, annually accounts for 
a million neonatal deaths. Furthermore, neonatal hypoxic ischemic encephalopathy (HIE) 
originating from perinatal asphyxia may lead to a variety of neurodevelopmental 
impairments. Therapeutic neuroprotective interventions such as hypothermia have 
significantly improved the prognosis of severe neonatal encephalopathy. 
Increased risk for intrauterine fetal hypoxia and perinatal asphyxia occur in various 
circumstances and pregnancy complications—such as intrauterine growth restriction (IUGR), 
which affects up to 10% of pregnancies. Timing the delivery in preterm pregnancy with 
severe IUGR is challenging, owing to balancing between risks related to prematurity and to 
fetal hypoxia. Another obstetric challenge concerns timing of delivery as well: Neonatal 
outcomes vary by gestational age also among term pregnancies. In pregnancies beyond 41 
gestational weeks, the risk for perinatal morbidity and mortality increases, probably due to 
the relative insufficiency of the aging placenta.  
Numerous methods such as fetal Doppler assessments and computerized cardiotocography 
help in monitoring placental function and fetal wellbeing. These methods, however, are not 
unequivocally efficient in predicting adverse neonatal outcomes in IUGR or in prolonged 
pregnancies. Furthermore, the time window for neuroprotective treatment in birth asphyxia 
is narrow, and additional methods for identifying those neonates who would benefit from 
neuroprotective actions are essential. We thus searched for biomarkers identifying those 
fetuses at risk for hypoxia-caused complications, and for predicting outcome after birth 
asphyxia. Erythropoietin (EPO) is a biomarker of chronic hypoxia, with high levels of EPO 
associating with increased risk for adverse outcome. S100B is a biomarker of brain- cell 
damage, and its levels rise in early phases of acute asphyxia. Copeptin, a by-product of 
arginine vasopressin (AVP) production, is a potential biomarker of birth asphyxia and HIE. 
Additionally, we aimed to evaluate the association of gestational age with perinatal asphyctic 
complications and long-term neurologic morbidity. 
The biomarker studies (I-III) were conducted in the University Hospital of Helsinki, Finland. 
Data on maternal pregnancy and delivery characteristics, and short-term neonatal outcomes 
such as Apgar score, originated from hospital charts. The study populations comprised 66 
pregnancies complicated by preterm IUGR, 93 low-risk term and prolonged pregnancies, and 
140 term neonates with birth asphyxia. Amniotic fluid samples for EPO evaluations we 
obtained by amniocentesis, at cesarean section, or vaginally at amniotomy. Umbilical serum 
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plasma samples for EPO, copeptin, and S100B assessments we collected at birth. Biomarker 
levels in amniotic fluid and umbilical plasma samples we measured by immunoassays. 
Normal amniotic fluid EPO levels we defined as < 3 IU/L, with abnormal levels exceeding 27 
IU/L. We considered as normal umbilical plasma EPO levels below 40 IU/L. 
The register-based cohort study on asphyxia and neurologic morbidity (IV) comprised  
1 138 109 women with singleton pregnancies and their newborns between 1989 and 2008 
in Finland. The Finnish Medical Birth Register (MBR), maintained by the National Institute for 
Health and Welfare (THL), provided data for this study. Statistical analyses we performed 
with the Statistical Package for Social Sciences (SPSS, Chicago, IL, USA), GraphPad Prism 6 
and SAS version 9.3 (SAS Institute, Inc, Cary, NC, USA). All tests were two-sided, with 
probability (p) values of < 0.05 as statistically significant. 
In IUGR pregnancies, abnormal amniotic fluid EPO levels were associated with decreased 
umbilical artery pH and base excess (BE) values, abnormal biophysical profile, and reversed 
end-diastolic flow in the umbilical artery. Most importantly, such abnormal EPO levels were 
associated with composite adverse neonatal outcomes defined as intraventricular 
hemorrhage, periventricular leukomalacia, cerebral infarction, or necrotizing enterocolitis (p 
< 0.001). In low-risk term and postterm pregnancies, EPO levels in amniotic fluid and in 
umbilical serum correlated with gestational age. Furthermore, EPO levels in amniotic fluid 
correlated with the levels in umbilical serum, even after vaginal delivery. Among low-risk 
pregnancies, however, EPO levels correlated with neither umbilical artery pH or BE, nor with 
other adverse pregnancy outcomes. In our study on biomarkers in birth asphyxia, only 
copeptin correlated with arterial pH. Its correlation with umbilical artery BE was significantly 
stronger than were the correlations of S100B or of EPO. Copeptin levels, significantly higher 
among neonates with birth asphyxia, we demonstrated to increase as a function of labor 
duration.  
In the cohort study, multivariate analysis demonstrated an increased risk for low (< 4) one- 
and five-minute Apgar score, CP, intellectual disability, sensorineural defects, and perinatal 
mortality among early-term births. Postterm birth resulted in increased risk for low one- and 
five-minute Apgar scores (< 4), low umbilical artery pH ≤ 7.10, and intellectual disability, 
whereas risks for CP, epilepsy, sensorineural defects, and perinatal mortality showed no 
increase. 
In conclusion, among preterm IUGR pregnancies, high amniotic fluid EPO levels were 
associated with decreased umbilical artery pH and BE, and with adverse neonatal outcomes. 
In selected risk-pregnancies, determining amniotic fluid EPO may thus be a useful additional 
tool in fetal surveillance and in optimizing delivery timing. In term pregnancies, EPO levels 
correlated with gestational age, probably explained by advancing gestation resulting in 
weakening placental function and relative hypoxemia. Among low-risk populations, 
however, EPO was not related to adverse delivery outcomes, and thus may not prove 
clinically useful in such populations. Furthermore, in cases of acute birth asphyxia, S100B and 
EPO as biomarkers may not prove valid. In contrast, copeptin has potential for routine use 
as a biomarker for acute birth asphyxia and neonatal distress. Future studies should 
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determine the correlation of biomarker levels at birth with severity of HIE and with long-
term neurological outcome following birth asphyxia. 
Concerning gestational age at birth, we found an increased risk for low Apgar score, 
increased neurologic morbidity, and perinatal mortality among early-term neonates. Among 
postterm births, the risk for birth asphyxia was increased. The long-term neurologic health 
impacts of postterm birth, however, were less important than previously expected, meaning 
that further studies on the optimal management of pregnancies beyond 41 gestational 
weeks are essential.  
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INTRODUCTION 
Fetal hypoxia occurs in a wide range of complicated pregnancies such as those involving 
maternal malnutrition, cardiovascular diseases, diabetes, obesity, hypertensive disorders, 
and  inflammatory conditions (1,2). Fetuses have numerous adaptive mechanisms to 
compensate for hypoxic conditions (2-4). Prolonged fetal hypoxia, however, leads to 
metabolic acidosis (5). The effects of intrauterine hypoxia on the fetus depend on the 
severity and duration of hypoxia, on gestational age at time of the hypoxic event, and on the 
etiology of the insult (1). Intrauterine hypoxia contributes to stillbirths, fetal growth 
restriction, and neurodevelopmental sequelae, and it influences long-term metabolic and 
cardiovascular health (3,6). Additionally, antepartum intrauterine hypoxia predisposes to 
hypoxic ischemic adverse events during birth (7,8). 
Worldwide, up to four million neonates are estimated to suffer from birth asphyxia annually 
(9). The majority will recover without developing long-term sequelae. However, continuous 
severe metabolic acidosis may eventually lead to vital organ and cerebral injury cascades, 
leading to neonatal hypoxic ischemic encephalopathy (HIE) or to death (10,11). The second 
most frequent cause of neonatal mortality, after preterm birth complications, is perinatal 
asphyxia, which contributes up to 25% of deaths within the first 28 days (12). Furthermore, 
perinatal asphyxia is estimated to account for millions of antepartum and intrapartum 
stillbirths, and contribute to equal numbers of permanent neurologic sequelae such as 
cerebral palsy (CP), epilepsy, intellectual disability, and sensorineural impairments (9,12). 
Neuroprotective treatments such as therapeutic hypothermia, have, in perinatal asphyxia 
among near-term and term neonates, substantially improved prognosis (13,14). 
The possibilities to influence intrauterine fetal well-being are scarce. The most important 
opportunity in preventing adverse outcomes is therefore timely delivery. This is a remarkable 
challenge, since unnecessary interventions can lead to excessive obstetric procedures and 
neonatal morbidity from prematurity. On the other hand, delayed responses to fetal distress 
may lead to stillbirth or severe neonatal asphyctic injury. Numerous methods such as fetal 
Doppler flow assessment and computerized cardiotocography (cCTG) serve to monitor 
placental function and fetal wellbeing in risk-pregnancies and help in delivery timing. The 
time-scale and sequence of alterations in these monitored parameters vary by gestational 
age and underlying pathologies (15-17). Identifying the specific pregnancies at risk for 
intrapartum fetal compromise and adverse neonatal outcomes is, however, challenging. 
New methods are called for in detecting individual high-risk pregnancies and optimizing 
delivery timing. 
Despite significant progress in perinatology and neonatology over the decades, neurologic 
morbidity after HIE remains significant (14,18-20). Furthermore, identifying those neonates 
who could benefit from neuroprotective treatments such as therapeutic hypothermia 
constitutes an additional challenge, owing to the restricted time window for these therapies. 
Risk for HIE increases with deepening acidemia (21,22), and five-minute Apgar scores 
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correlate with risk for neurological disability (23). However, the sensitivity and specificity of 
umbilical artery pH values and Apgar scores regarding outcomes following HIE are low (11). 
Clinical neurological signs during the immediate neonatal period indicate initiation of 
therapies and are somewhat better predictors of outcomes (24). Reliable and swift additional 
methods in selecting neonates for treatment and predicting outcome after birth asphyxia 
are urgently needed, with several neonatal biomarkers under study in recent years (25,26). 
Approximately 10% of neonates are born small for gestational age (SGA) (27,28). The subject 
of fetal growth is critical, since, in fetal growth restriction, risks for perinatal asphyxia and 
HIE, intracranial hemorrhage, meconium aspiration, immune dysfunction, hypoglycemia, 
and other metabolic abnormalities are increased (29,30). Moreover, suboptimal fetal growth 
is accountable for 25% to 43% of all stillbirths (31-33). 
Pregnancy outcomes vary by gestational age at birth, even among term pregnancies. The 
optimal gestational length appears to be reached between the 39+0 and 41+6 gestational 
weeks (GW), with risk for adverse outcomes increased outside this period (34). Post-term 
pregnancies, at or beyond 42+0 GW, account for approximately 14% of stillbirths worldwide 
(12,35). The underlying mechanism is assumed to be aging of the placenta and subsequent 
relative placental insufficiency, thus predisposing the fetus to hypoxia. Gestational age-
associated risks, however, form a biological continuum. Consequently, a U-shaped 
relationship occurs between adverse pregnancy outcomes and gestational age (34). Risks for 
perinatal mortality and morbidity increase in pregnancies beyond 41+0 GW (36,37). Recently, 
increased short- and long-term morbidity such as excessive neonatal admissions, prolonged 
hospitalizations, developmental delay, and CP have been related to early-term births 
between 37+0 and 38+6 GW (34,38). In European and North American countries, the 
proportion of postterm birth is decreasing and that of early-term birth increasing (39,40). In 
Finland, however, these rates have remained relatively stable until recent years (41). Some 
questions as to the significance of gestational age on birth asphyxia, long-term neurologic 
morbidity, and perinatal mortality among term pregnancies in Finland have, however, arisen. 
Levels of erythropoietin (EPO), a primary hormone regulating erythropoiesis, rise in response 
to hypoxia in adults, newborns, and fetuses (42). EPO level in amniotic fluid correlates with 
its level in fetal plasma during pregnancy (25). Increased EPO levels in amniotic fluid and in 
umbilical cord serum occur in various complicated pregnancies and are associated with an 
increased risk for adverse neonatal outcomes such as decreased umbilical artery pH and base 
excess (BE), and need for neonatal intensive care unit admission (25). Amniotic fluid EPO 
(am-EPO) may be considered as a biomarker of chronic fetal hypoxia. Data on am-EPO in 
relation to umbilical artery Doppler flow abnormalities and neonatal outcome in pregnancies 
complicated by intrauterine growth restriction are lacking. Such data might assist in 
identifying fetuses suffering from aggravating hypoxia and assist in timing of delivery. 
Furthermore, identifying those specific postterm pregnancies at increased risk for adverse 
outcome is especially challenging. Whether am-EPO can identify these risk pregnancies is 
unknown. 
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Protein S100B, mainly produced in the central nervous system, is considered a biomarker of 
brain distress and neuronal cell injury (19,43). It is associated with various conditions 
including traumatic brain injury and stroke, as well as with neurodegenerative, congenital, 
and psychiatric diseases (43,44). High S100B concentrations in amniotic fluid may predict 
intrauterine death (45). Elevated cord plasma S100B concentrations are related to acidemia 
and asphyxia at birth (46,47). Furthermore, in birth asphyxia, elevated umbilical cord S100B 
concentrations may predict development of moderate to severe HIE, and predict risk for 
neurological damage at age six (47). 
Copeptin, a stable by-product of arginine vasopressin (AVP), is a novel biomarker serving as 
a diagnostic and prognostic marker for adult emergency departments (48-50). AVP has 
crucial effects on cardiac function and physiologic homeostasis in various stress conditions. 
During normal birth, the fetal hypothalamic-pituitary-adrenal (HPA) axis activates and results 
in AVP release. This is further accelerated by numerous stress factors such as infections, 
intrauterine growth restriction (IUGR), and acidosis or birth asphyxia (51-53). The utility of 
copeptin in comparison with that of other asphyxia biomarkers and the relationship of 
copeptin to delivery modes in planned vaginal births and duration of delivery both demand 
study.  
This study evaluated the significance of EPO in management of pregnancies complicated by 
IUGR, and of prolonged pregnancies. Additionally, we evaluated and compared umbilical 
cord blood biomarkers—EPO, S100B, and copeptin—in neonates with birth asphyxia to test 
these potential biomarkers in patient selection for therapeutic interventions. Moreover, we 
assessed the association of gestational age with perinatal asphyxia and long-term neurologic 
morbidity in term and post-term pregnancies. 
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REVIEW OF THE LITERATURE 
CHARACTERISTICS OF FETAL PHYSIOLOGY 
The intrauterine environment is relatively hypoxic as compared to the environment after 
birth. The partial oxygen-pressure gradients between maternal blood, placenta, and fetal 
blood and tissues determine fetal oxygenation (54). Maternal arterial partial oxygen pressure 
is from 80 to 90 mmHg, but in the fetal compartment, pressure ranges from 25 to 30 mmHg 
(54). The highest fetal oxygen saturation—found in the umbilical vein—ranges between 70% 
and 80% (4). Fetal tissue oxygenation, however, is comparable to oxygenation during 
postnatal life, as a result of several delicate compensation mechanisms (54). 
Hematologic adaptations 
The relatively low oxygen environment induces fetal erythropoiesis via hypoxia-inducible 
factors and EPO synthesis, thus increasing oxygen transferal capacity (4). Furthermore, fetal 
hemoglobin has high oxygen affinity which facilitates the uptake of oxygen from the placenta 
to the fetal circulation (4,54). Local factors such as tissue acidity modulate oxygen delivery 
from fetal blood to peripheral tissues (4). 
Circulation 
Oxygenated blood flow from the placenta is directed to the left ventricle and towards the 
developing brain and heart through anatomic shunts (4). High cardiac output ensures high 
blood flow to the fetal tissues (54). Adaptations of cardiac output occur mostly by 
modulations in heart rate. These modifications are limited, however, due to the immaturity 
of cardiac sympathetic innervation and myocardial contractility (4). The fetal pulmonary 
circulation consists mostly of deoxygenated blood with a low saturation of 55%. Initially, 
pulmonary blood flow covers approximately 10% of cardiac output, but its proportion, with 
advancing gestation, increases up to 50% (4). 
INTRAUTERINE HYPOXIA 
Fetal hypoxia occurs in a wide range of pathologic circumstances during pregnancy, ones 
such as maternal malnutrition, smoking, cardiovascular diseases, diabetes, obesity, and pre-
eclampsia, as well as in inflammatory conditions like chorioamnionitis (1,2). Intrauterine 
hypoxia is a major obstetrical challenge contributing to stillbirths, fetal growth restriction, 
neurodevelopmental complications, and long-term metabolic and cardiovascular health 
effects (3,6). However, the exact prevalences of antepartum hypoxia and asphyxia are 
unknown (55). 
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Definitions 
Hypoxia occurs when oxygen demands of the tissue exceed the available supply (56). Normal 
oxygen tension in fetal arterial blood is close to the hypoxia level in adult tissues. This relative 
hypoxemia predisposes the fetus to a lower threshold of oxygen insufficiency (3). In 
uteroplacental hypoxia, maternal oxygenation is normal, but the uteroplacental circulation 
is impaired, leading to inadequate fetal oxygenation causing, first, decreased oxygen 
concentration in arterial blood, and ultimately in fetal tissues (57). Oxygen demands of the 
placenta and the fetus increase along with advancing pregnancy (6). 
Etiology of fetal hypoxia 
Placental dysfunction is most commonly due to suboptimal remodeling of maternal vessels 
and superficial trophoblast invasion during early stages of placentation (58). Deficient spiral 
artery remodeling leads to malperfusion of the placenta, inducing oxidative cell stress, 
selective suppression of protein synthesis, and reduced cell proliferation (59). Subsequently, 
reduction in placental volume and surface area for transport ensues. Secondary alterations 
involving fetal arteries cause increased resistance within the umbilical circulation, resulting 
in further impairment of placental function (59). Additionally, inflammatory conditions may 
lead to increased placental vasculature resistance and to oxygen deprivation (2). Regardless 
of the mechanism initiating placental pathology, abnormalities in  placental development or 
in metabolism result in placental and fetal hypoxia (3,6). Prolonged fetal tissue hypoxia leads 
to accumulation of lactic acid and results in metabolic acidosis (5). In placental insufficiency, 
respiratory gas exchange is impaired, thus exposing the fetus to hypercapnia and respiratory 
acidosis in addition to hypoxia and metabolic acidosis, leading to fetal asphyxia (60). 
Fetal compensatory mechanisms in intrauterine hypoxia 
The fetus has several adaptive mechanisms to compensate for hypoxic conditions. 
Hemodynamic responses conserve the oxygenation of organs critical for survival. Energy 
metabolism turns towards increased glycolysis and utilization of anaerobic energy sources, 
and genes necessary to alter cell metabolism accordingly are activated during hypoxia (3). 
The fetus can impede many oxygen-consuming functions (2). For instance, fetal movements 
are reduced as an adaptation to impaired oxygenation (61). The affinity of fetal hemoglobin 
for oxygen decreases during fetal acidosis, thus enhancing tissue oxygenation (4). If the 
hypoxia persists, and the compensation mechanisms become insufficient, fetal distress and 
eventually demise ensues. 
Cardiovascular adaptations. During periods of impaired oxygen delivery, fetal chemoreflex 
activation rises fetal blood pressure. This mechanism directs more blood flow to the 
umbilical-placental circulation, thus facilitating oxygen uptake from the placenta (62). At the 
same time, deceleration of the fetal heart rate occurs, leading to more efficient gas exchange 
owing to the slower blood flow (2). Additionally, cardiovascular changes can reduce the 
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adverse effects of tissue hypoxia via redistribution of blood flow to the brain, the coronary 
arteries, the adrenals, and the upper body. As cerebral vasodilatation occurs and vascular 
resistance increases in the lower body, cardiac output shifts towards left ventricle outflow 
tract (63,64).  
These responses are regulated by vagal reflexes, by vasoactive hormones such as 
catecholamines and vasopressin, and by local vascular tone modifications of nitric oxide (NO) 
and reactive oxygen species (ROS) (2). In chronic hypoxia, redistribution of the circulation is 
sustained, thus inducing physiological changes such as reduction in smooth-muscle and 
endothelial function and constantly increased flow in the cerebral and myocardial 
vasculature (62). Furthermore, a persistent increase in peripheral vascular resistance leads 
to remodeling of the cardiomyocytes and the walls of the heart and major vessels (2). 
Hematologic changes. The major part of the intracellular adaptive responses in continuous 
hypoxia are regulated by transcription factor HIFα (hypoxia-inducible factor alpha) (54). 
Stabilization and activation of HIF-1 in hypoxia leads to activation of transcription of multiple 
genes, such as those producing EPO and VEGF (vascular endothelial growth factor), thus 
enhancing tissue oxygenation (54). Consequently, in tissue hypoxia, erythropoiesis, 
nucleated red blood cells, and hematocrit increase (6). 
Metabolic and endocrine compensation. In hypoxia, swift hypothalamus-pituitary-adrenal 
(HPA) axis activation plays a key role in initiating fetal protective mechanisms. A significant 
increase in glucocorticoids influences plasma glucose, lipid, and protein concentrations, thus 
maintaining fetal homeostasis (1). The sympathetic nervous system is activated and 
catecholamines released regulate fetal cardiovascular and metabolic stress responses (65). 
Such responses are crucial in acute stress circumstances, but in chronic conditions they have 
the potential to alter regulation mechanisms of the endocrine system and metabolism 
permanently. Indeed, in chronic hypoxia, the adrenal sensitivity to adrenocorticotropic 
hormone (ACTH) and the cortisol response are attenuated as compared to responses in 
normal pregnancy, and adrenal medullary responses appear to adapt to chronic hypoxia, as 
well (62). Thus, the adverse environment caused by intrauterine hypoxia predisposes the 
fetus to a variety of cardiovascular and metabolic pathologies later in life (1,66). 
Fetal consequences of hypoxia 
The effects of intrauterine hypoxia on the fetus vary by severity and duration of hypoxia, 
gestational age during hypoxia, and etiology of the insult (1). As a consequence of placental 
insufficiency, both nutrient and oxygen transfer are reduced (6). This leads to failure of the 
fetus to achieve its optimal growth potential (27). Fetal growth restriction, especially when 
not detected antenatally, is a major risk factor for stillbirth (67). Hypoxia, caused by placental 
insufficiency, is assumed to be an important contributor to most fetal deaths, also in high-
income countries (68,69). 
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Antepartum intrauterine hypoxia may cause increased vulnerability to hypoxic ischemic 
adverse events at birth, especially in regard with fetal growth restriction (7,8). Recurrent 
undetected asphyctic events can occur during pregnancy, and this may lead to continuous 
and more severe injury during delivery (5,70). In a substantial portion of birth asphyxia cases 
the origin of asphyxia is antenatal (55). 
Long-term consequences of intrauterine hypoxia 
Neurologic implications. In hypoxia the metabolic rate of the brain tissue decreases, 
probably to reduce its oxygen demands (62). In the fetal brain, chronic hypoxia causes 
production of reactive oxygen species (ROS), potentially leading to cell damage and 
apoptosis (62). Fetal hypoxia, especially when related to growth restriction, contributes to 
long-term cognitive and neurologic abnormalities, (71). In term pregnancies, the etiology of 
CP is prenatal for approximately 70% to 80% of cases (72), one of the major contributors 
being fetal asphyxia (73). Birth asphyxia is associated with 10% of all cases of CP and 20% of 
CP among children born at term (5). In preterm births, however, antenatal causes explain 
roughly 17% of CP cases (73). Among preterm neonates, asphyxia is more frequently 
moderate to severe and leads to a greater risk for long-term morbidity and death, than 
among term neonates (55). 
A recent study on fetal sheep demonstrated that chronic hypoxia leads to significant 
alterations in fetal neurodevelopment (74). The findings included reduced cortical folding, 
reduced neuronal density, hypervascularity, and impaired myelination. Such structural 
changes are associated with subsequent delay in cognitive performance, and resemble those 
abnormalities found among newborns with growth restriction and congenital heart diseases, 
being injured by intrauterine hypoxia (74). 
A recent animal study on gene expression patterns has revealed inflammation patterns in 
the fetal brain after a hypoxic episode (62). Additionally, live bacteria identical to species in 
the placenta have been found in the fetal brain after transient hypoxia, possibly related to 
increased vascular permeability resulting from hypoxia (62). The significance of this recent 
discovery is not yet elucidated. 
Fetal programming. Intrauterine hypoxia causes long-term health effects and increased risk 
for chronic diseases via fetal programing (75). Hypoxia causes an increase in reactive oxygen 
species (ROS), which can trigger long-term changes in gene expression patterns (3). Such 
epigenetic changes may affect multiple enzymes involved in steroidogenesis and stress 
hormones, potentially predisposing the fetus later in life to chronic cardiovascular and 
metabolic diseases. Intrauterine hypoxia is associated with depressed cardiac performance 
and with cardiomyopathies (3). In addition, hypoxia affects lung development by reducing 
the pulmonary circulation and breathing movements (4). Activation of hypoxia-induced 
factors lead to remodeling of the pulmonary vasculature and to increased vascular 
resistance, predisposing to development of pulmonary hypertension (76). 
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ANTENATAL AND INTRAPARTUM FETAL MONITORING 
The purpose of fetal antenatal surveillance is detection of signs of evolving hypoxia and 
activation of adaptation mechanisms in its early stages. In most cases, fetal deterioration 
follows a certain pattern, beginning with changes in heart-rate tracings, followed by 
decrease in amniotic fluid volume and in fetal movements (77). Thus, intensive monitoring 
and treatment can focus on pregnancies with fetuses at increased risk for adverse outcomes, 
with timing and mode of delivery planned appropriately. 
On the other hand, the main objective of fetal monitoring during labor is to identify those 
fetuses at immediate risk for perinatal asphyxia, and to prevent potential serious 
consequences such as HIE or perinatal death. Assurance of fetal wellbeing without 
unnecessary obstetric interventions is, as well, a priority (78). 
Ultrasonography 
Growth assessment. Evidence of improving pregnancy outcomes by routine late pregnancy 
ultrasound after 24 GW in a low-risk population is lacking (79). However, identifying small-
for-gestational age (SGA) fetuses before delivery significantly reduces risk for adverse 
outcomes such as stillbirth, low Apgar score and umbilical pH, HIE, intracranial hemorrhage, 
neonatal seizures, CP, and infant death (30). However, identifying SGA during pregnancy is 
challenging, even by applying appropriate methods. A substantial proportion of fetuses that 
are SGA, up to 35%, remain undetected before birth (80). 
Biophysical profile scoring (BPP) estimates fetal wellbeing by describing these variables: 
Fetal movements, tone, amniotic fluid volume, breathing, and heart rate activity (81). BPP 
reflects fetal metabolic state and oxygenation, along with the function and maturation 
profile of the nervous system (81). Evidence of BPP providing benefits for pregnancy 
outcome is controversial. A clear correlation between fetal acidosis and decreased fetal 
movements does exist (61), and studies have demonstrated an association of abnormal BPP 
with prenatal mortality and CP (82). Pregnancies with poor perinatal outcomes after women 
observing reduced fetal movements may reach 25%, and in one study more than half of the 
population reported decreased movements before fetal demise (83). One systematic review 
of high-risk pregnancies, however, found no improvement in perinatal outcome—no 
reduction in perinatal deaths nor low Apgar score at 5 min—but found an increased risk for 
cesarean section by means of fetal surveillance with BPP scoring (84). 
Amniotic fluid volume assessment is a part of BPP scoring. Oligohydramnios is often 
associated with placental dysfunction and is considered to reflect decreased renal perfusion 
due to redistribution of the circulation (85). Reasonably, in one systematic review, an 
association of adverse delivery outcomes—such as Apgar score < 7 at 5 minutes and cesarean 
section for fetal distress—appeared with oligohydramnios (86). However, controversial 
studies do exist with no evidence of such increased risk, even among complicated high-risk 
pregnancies (85,87). Amniotic fluid volume can be estimated by measuring the deepest 
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vertical pocket or the amniotic fluid index, and these methods are equivalent in prevention 
of adverse outcomes (88). 
Doppler flow ultrasound assessments are extensively utilized in uteroplacental hypoxia to 
detect fetal hemodynamic stress responses. Superficial trophoblast invasion during early 
stages of placentation and suboptimal remodeling of maternal vessels leads to high-
resistance uteroplacental circulation and placental dysfunction (58). These abnormalities are 
detectable by Doppler flow changes such as increased resistance and persistent notching in 
uterine artery blood flow during early pregnancy (89). 
Changes in fetal circulation are often progressive and follow certain patterns (15). Umbilical 
artery Doppler parameter alterations appear when more than half of the placental 
circulation is lost (90). The severity of a Doppler flow abnormality is proportional to the 
degree of hypoxia and acidemia. Thus, absent or reversed end diastolic flow patterns are late 
signs of a far advanced process (63,91).  In high-risk pregnancies, umbilical artery Doppler 
ultrasound surveillance reduces risk of perinatal death (90). Following umbilical artery 
Doppler alterations, reduction in blood flow impedance in the middle cerebral artery (MCA) 
usually appears as a “brain sparing” effect (92). According to a recent systematic review and 
meta-analysis, MCA Doppler alone, however, show good predictive accuracy (93). 
Alterations in cerebroplacental ratio (CPR)—changes in relations between MCA and umbilical 
artery flow—are, however, associated with perinatal composite adverse outcome and 
emergency cesarean delivery for fetal distress (94,95). 
As the cerebral and placental vascular impedances change, resistance in aortic blood flow 
increases (15,92). Abnormalities in aortic isthmus Doppler flow may help in early 
identification of fetuses at risk for intrauterine compromise and help in predicting perinatal 
and neurodevelopmental outcomes (96). As hypoxia progresses, an increase in venous flow 
resistance occurs, owing to hypoxemia of the myocardium (15,97). Alterations in venous 
Doppler flow profiles correlate well with fetal acidosis (91,97). Retrograde ductus venosus a-
wave and pulsatile flow in the umbilical vein (UV) indicate fetal cardiac compromise (98). 
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Figure 1. Intermittent absent end diastolic flow in monochorionic twin pregnancy complicated 
by selective intrauterine growth restriction. By author 
Antenatal cardiotocography and computerized cardiotocography 
Cardiotocography (CTG) is a method widely used in fetal surveillance. Basically, changes in 
heart rate patterns can predict ominous fetal hypoxia (60). During pregnancy, accompanying 
the developing autonomic nervous system and fetal maturation, heart rate patterns evolve 
(60). Heart rate baseline decreases, and the variability increases. The behavioral stages with 
this episodic activity and accelerations usually appear around 25 to 28 GW (6,99). 
Intrauterine hypoxia can delay maturation of the nervous system and reduce fetal 
responsiveness and also reduce the emergence of various behavioral stages (6,100). 
Visual interpretation of the fetal heart rate patterns is subjective, and its consistency is 
affected by high intra- and interobserver variability (101). Evidence of improvement in 
reducing perinatal morbidity or mortality by utilizing traditional CTG monitoring is lacking 
(102). Computerized CTG (cCTG) is, however, a more objective method (99). The most useful 
cCTG indicator of fetal antepartum well-being is fetal heart rate variation, with the normal 
values of short-term variation by gestational age being well reported (99). In certain risk-
pregnancies, reduction in short-term variability predicts metabolic acidosis and adverse 
neonatal outcomes (103). Some data exists on improvement in perinatal survival rates by 
use of cCTG, but the level of evidence is low and needs further study (102). 
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Intrapartum cardiotocography 
Fetal heart rate monitoring is generally considered the gold standard of intrapartum fetal 
surveillance, with CTG tracings classified as normal, suspicious, or pathological (100). The 
basic normal intrapartum CTG features are described in the FIGO guidelines, including 
normal baseline between 110 and 160 bpm, normal variability with a bandwidth amplitude 
of 5 to 25 bpm, and accelerations from baseline being a sign of a neurologically responsive 
fetus (100). Decelerations are defined as decreases in the fetal heart rate below baseline of 
more than 15 bpm in amplitude and lasting more than 15 seconds. Decelerations are 
classified according to physiologic background as early, variable, late, or prolonged (100). 
Chemoreceptor-mediated heart rate responses, and late and prolonged decelerations are 
often related to fetal hypoxia or acidosis. Regular re-evaluation of the tracings during 
delivery is recommended, especially during the second stage of labor when fetal hypoxia 
may develop rapidly.  
Numerous studies on CTG analysis have indicated considerable disagreement and variation 
(100,104). The early studies revealed that only a minority of suspicious and even pathological 
fetal heart rate recordings were associated with fetal acidemia (105). Specificity and the 
positive predictive value of suspicious and pathologic CTG tracings for acidemia and low 
Apgar score at birth are low (106). According to a recent Cochrane review, continuous CTG 
compared to intermittent auscultation had no effect on perinatal death, on CP, or on cord 
blood acidosis rates (107). Neonatal seizure rates, however, were lower in the continuous 
CTG group. Risks for cesarean section or instrumental vaginal delivery were higher in the 
group with continuous CTG tracing. The outcomes were comparable among low- and high-
risk subgroups (107). 
 
Figure 2. Pathologic CTG in the end of the second stage of labor. Umbilical artery pH at birth 
was 6.99 and BE -12.00, with Apgar score 4/6/6. By author 
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Adjunctive intrapartum surveillance technologies 
Several technologies adjunctive to CTG allow fetal intrapartum surveillance, both to identify 
evolving hypoxia and to reduce unnecessary interventions (108). 
Fetal scalp-blood sampling (FBS) for pH or lactate is an accessory, second-line method to 
CTG for assessing fetal wellbeing during labor. At birth, moderate neonatal acidosis can be 
defined as pH below the 10th percentile, meaning pH below 7.15 (109). Acidosis can be due 
to accumulation of pCO2, leading to increased production of H+ ions. Such a condition can 
occur and resolve rapidly and is infrequently associated with long-term adverse outcomes 
(109). Metabolic acidosis, however, is related to prolonged tissue hypoxia. Anaerobic 
metabolism produces lactate and H+ ions, thus depressing blood and tissue pH. This type of 
acidosis takes a longer time to resolve, with increased  risk for impaired neurologic 
development and end-organ damage (109). Metabolic acidosis is defined as severe when the 
arterial base deficit is > 12 mmol/L, or lactate > 10 mmol/L. 
Fetal scalp-blood analysis (FBS) was introduced almost 60 years ago to improve diagnosis of 
intrapartum fetal acidemia (105). The technique has some disadvantages; it is invasive and 
has several technical challenges, and each sample reflects only the current situation. 
Additionally, a blood sample from the fetal scalp probably does not represent the precise 
situation in the central circulation. However, when lactate measurement is normal during 
the last hour of labor, it strongly predicts normal oxygenation at birth (108). In detecting 
hypoxia during labor, FBS analyze for lactate and for pH are equally effective (110). Some 
evidence exists that FBS, as a method adjunct to CTG, reduces rates of operative 
interventions (109). Clear evidence as to the beneficial effect of fetal blood sampling on 
neonatal outcomes is lacking (107). 
Fetal stimulation. Observational studies have shown that appearance of acceleration and 
normalization of CTG tracing in response to scalp stimulation is a consistent sign of fetal 
wellbeing, a negative predictive value comparable to a pH of 7.25 with FBS (108). A positive 
fetal scalp-stimulation test may reduce the need for FBS (108). 
STAN. During hypoxia, fetal electrocardiogram ST-segment changes precede failure of 
cardiovascular function (111). Computer-assisted combined analysis of CTG and ST 
morphology changes, the STAN® concept, has been utilized since 2000 (108). The potential 
advantages of this technique are its less invasive approach and its continuous data on fetal 
status. The results of numerous randomized controlled trials (RCTs) and observational 
studies on ST segment analysis are controversial (108). Currently, the latest meta-analysis 
showed that monitoring of ST changes significantly reduces rates of operative deliveries and 
the need for FBS (112). The effect on neonatal acidosis has been debated, but in recent 
observational studies, a decrease in metabolic acidosis incidence has been detectable 
(113,114). Importantly, commencement of ST analysis technique is associated with a long-
lasting learning curve, and the advantages of the method may emerge after a considerable 
delay following its introduction (114).  
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MANAGEMENT OF SELECTED RISK PREGNANCIES 
The primary objective of fetal surveillance is to improve perinatal outcome by reducing 
mortality and morbidity. Since the options to influence fetal well-being during pregnancy are 
few, the most important opportunity for preventing adverse outcomes is timely delivery. 
This is, however, a major obstetric challenge. Unnecessary interventions can lead to 
excessive and potentially harmful obstetric procedures and to neonatal morbidity from 
prematurity. On the other hand, stillbirth or severe neonatal asphyctic injury can result from 
delayed actions on fetal distress. 
Intrauterine growth restriction (IUGR) 
Incidence, background, and definitions. Approximately 10% of neonates are born small for 
gestational age (27,28). In high-income countries, fetal growth restriction occurs in 3% to 9% 
of all births (115), a prevalence significantly—more than six-fold—higher in low- and middle-
income countries (116). 
Numerous maternal and fetal factors can lead to impaired fetal growth. These include 
environmental and maternal problems such as infection, malnutrition, reduced 
uteroplacental blood flow, and placental insufficiency, as well as fetal factors like 
chromosomal and structural abnormalities (70,117). Fetal growth restriction can be 
classified into three types according to fetal growth patterns (118). Such patterns generally 
reflect the etiology of the growth disorder, as well. In symmetric growth restriction, a 
proportional decrease in size of the head, abdomen, and long bones occurs. These fetuses can 
either be constitutionally small but normally developed fetuses with no risk for complications, or 
be fetuses with congenital chromosomal or genetic abnormalities leading to severe growth 
retardation. Fetuses with asymmetric FGR mainly have a smaller abdominal size, but the head and 
long bones are within normal limits. In such a growth pattern, the primary etiologic factor is 
placental insufficiency, putting these fetuses at increased risk for intrauterine hypoxia. In the third 
pattern, features of both the other two patterns are manifested, and etiologic factors consist of 
embryonic infections and toxic agents at early stages of pregnancy (118). 
Diagnostic criteria for fetal growth restriction (FGR) or intrauterine growth restriction (IUGR) 
have, some extent of variation, but generally these terms refer to a fetus who fails to achieve 
its expected genetic growth potential (27). The WHO has defined FGR as fetal growth below 
the third percentile (-2 SD), but in clinical practice the most generally applied definitions 
include estimated weight or abdominal circumference less than the 10th percentile 
(80,119,120). Such definitions include heterogenous groups of SGA fetuses comprising both 
the constitutionally small fetuses not at risk for adverse outcomes, and the fetuses not 
reaching their growth potential due to external factors; these are at increased risk for 
antenatal and postnatal complications (93,121-123). Nevertheless, in a major proportion of 
SGA pregnancies, fetuses are growth restricted, and most of the growth-restricted fetuses 
are SGA (30). Recently, an international expert panel introduced a consensus definition of 
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fetal growth restriction considering also the grade and distribution of growth restriction as 
well as Doppler flow parameters (123). 
Controversy exists as to the advantages of individualized reference curves for fetal growth 
estimation. Proposals as to improvement of prediction of SGA neonates and adverse 
outcomes by customized growth charts are several (124-126). One recent study, however, 
has demonstrated similar fetal and newborn growth patterns among diverse geographical 
surroundings and ethnicities in which environmental characteristics are similar (127). Among 
fetuses identified as SGA, a change in abdominal circumference may be useful in detection 
of growth restriction (128). The time interval between the measurements should be long 
enough, up to three weeks, to avoid false positive results (129). 
The two distinct phenotypes of IUGR are early and late-onset. They differ by timing of 
occurrence, patterns of evolution and of Doppler-flow parameters, and neonatal outcome 
(17,130). Considering perinatal outcomes, the best division between the two IUGR forms is 
at 32 GW (131). Early IUGR is more often related to pre-eclampsia, and the progression is 
more predictable (17,132). Late-onset IUGR is more difficult to detect, and more prevalent 
than is early IUGR (16,133). 
Outcomes. The subject of fetal growth is crucial, since growth-restricted fetuses are at 
increased risk for mortality and morbidity (17,120,122). Among normally growing fetuses, 
risk for stillbirth is approximately 2/1000 births (134,135), a risk significantly higher among 
growth-restricted fetuses and proportional to the severity of growth restriction, three- to 
nine-fold that of normally growing fetuses, increasing up to 2.5% among fetuses weighing 
less than the 2.5th percentile (134,135). Consistent with these data, suboptimal fetal growth 
accounts for 25% to 43% of all stillbirths (31-33). 
Incidence of neonatal death, of low Apgar score ≤ 3 at five minutes, and of umbilical artery 
pH ≤ 7.00 are significantly higher among term infants with birth weights at or below the 3rd 
percentile (30,136). Additionally, in this group, the need for intubation at birth, incidence of 
seizures, and sepsis are more common (136). In fetal growth restriction, the risk for perinatal 
asphyxia and moderate to severe HIE, intracranial hemorrhage, meconium aspiration, 
polycythemia, thrombocytopenia, immune dysfunction, hypoglycemia, and other metabolic 
abnormalities are increased (29,30). Those preterm neonates in particular with IUGR are 
more susceptible and have excessive prematurity-related morbidity: Hypothermia, 
hyperbilirubinemia, respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary 
hemorrhage, necrotizing enterocolitis (NEC), infections, and intraventricular hemorrhage 
(17,29,137). 
Furthermore, fetal growth restriction is associated with long-term adverse outcomes such as 
intellectual disability, CP, and cardiovascular and metabolic diseases (30,75,115). Brain-
tissue volume alterations occur in association with IUGR (138). Distinct brain areas and 
neurological functions are affected at different stages of pregnancy, suggesting the evolving 
pathophysiology and vulnerability of the fetal brain with gestational age (139). A recent 
systematic review of neurodevelopmental outcomes after IUGR concluded that such 
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children are at risk for poorer neurodevelopmental outcomes from 6 months to 3 years of 
age (33). A wide variety of impairments of cognitive functions including delay in language 
and in adaptive behavioral development, and in learning and attention disabilities, as well as 
motor delay (33). Furthermore, children with IUGR had lower academic achievement, lower 
intelligence quotients (IQs), and more neurophysiological problems at age 9 to 10 years, than 
for normally growing gestational age-matched controls (33,140). 
Management of IUGR pregnancy - timing of delivery. The purpose of antenatal surveillance 
in fetal growth restriction is to predict fetal asphyxia and enable delivery before irreversible 
injury or stillbirth occur. When fetuses at risk are identified, and monitoring is implemented 
efficiently, surveillance can reduce perinatal death risk significantly (90). However, timing of 
delivery in preterm pregnancy with severe IUGR constitutes a major obstetric challenge. 
Gestational age at birth strongly affects neonatal outcome, and the timing of the delivery 
thus includes critical balancing between the risks related to prematurity and inadequate 
tissue perfusion (141). In one large study on early growth restriction, gestational age was the 
primary determinant of survival until 27 GW, and of intact survival until 29 weeks (142). 
Indeed, before 28 weeks, prolongation of pregnancy by one day raised the chance of survival 
by 2% (142). Delaying delivery may lead to increased rate of stillbirths. However, a few days’ 
delay does not affect overall perinatal mortality and appears to improve neurologic 
outcomes at age two (143,144). In a cohort study of near term SGA fetuses, delivery before 
38 weeks was associated with higher risk of perinatal mortality than was expectant 
management (145). Beyond that point, continuing the pregnancy began to increase the 
perinatal mortality risk (145). 
Several methods are available in surveillance of growth-restricted fetuses, ones such as CTG, 
biophysical profile assessment, and Doppler flow ultrasound. Some controversy as to the 
acuity and utility of the test combinations does exist. Among the majority of early IUGR 
fetuses, deterioration of parameters follows a classical pattern along with worsening hypoxia 
and acidemia (15,132,146). First appear alterations in Doppler parameters—in umbilical 
artery, MCA, and venosus indices—followed by reduced fetal breathing movement and 
amniotic fluid volume. Finally, loss of fetal movement and tone occurs, along with CTG signs 
of fetal distress (15,132,146). The time scale and sequence of alterations varies by 
gestational age and underlying pathology (15,16). In late onset IUGR, umbilical artery 
Doppler does not necessarily reveal fetal distress, and the classical sequence of Doppler 
alterations does not always appear (17,147,148). CTG changes reflecting brain hypoxia may 
occur at earlier phases of the sequence (17). 
Computerized CTG tracings utilizing short-term variation analysis are better predictors of 
fetal distress in growth restriction than are traditional CTGs (103,149). Low short-term 
variation (STV) ≤ 3 ms is associated with high rates of metabolic acidemia (54%) and of 
neonatal death (8%) (103). Generally, STV tends to be lower among growth-restricted 
fetuses (150). According to current recommendations, computerized CTG analysis should be 
the preference in surveillance of SGA fetuses (119). 
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Biophysical profile score is a common tool for evaluation of hypoxia-related changes, with a 
reduced score associated with fetal acidosis, prenatal mortality, and CP (82,151). However, 
in chronic hypoxia, fetal movements can return to close to normal patterns, and ultimate 
loss of movements may appear as a late manifestation of fetal distress (60,146). Current 
evidence reveals high false-negative rates in detecting fetal acidemia among SGA fetuses; 
BPP is thus not considered an accurate surveillance method in such pregnancies (149,152). 
Reduced amniotic fluid volume can occur in an early phase of placental insufficiency (92), 
but as an isolated sign it fails to predict adverse pregnancy outcomes (85). 
Doppler flow studies are in wide use in evaluation of growth restriction and of placental 
function among fetuses with growth below the 10th percentile (153). Vascular abnormalities 
in tertiary villi lead to high-resistance placental circulation and placental insufficiency 
(153,154), leading to progressive changes in Doppler flow profiles in maternal and fetal 
vessels (153,154). 
Umbilical artery Doppler velocimetry is recommended as a primary surveillance method in 
fetal growth restriction (90,119). Especially associated with intrauterine hypoxia, and 
perinatal morbidity and mortality is absent or reverse end-diastolic flow in the umbilical 
artery (141,155,156). In addition, abnormal umbilical artery Doppler is related to long-term 
adverse neurologic outcomes (33). In high-risk pregnancies such as growth restriction, 
current evidence shows umbilical artery Doppler assessment significantly reducing risks of 
perinatal death and unnecessary obstetric interventions (90,154). Nevertheless, despite 
normal umbilical artery flow, small-for-gestational-age fetuses may still be at increased risk 
for neonatal morbidity and suboptimal neurodevelopmental outcome (157,158). 
Redistribution of blood flow and cerebral vasodilatation both rise in response to chronic 
hypoxia. Brain-sparing as a neuroprotective reflex, nonetheless, cannot entirely compensate 
for the effects of hypoxia on neural tissues (159). Increased MCA end-diastolic flow leads to 
alterations in Doppler parameters such as reduced MCA PI or cerebroplacental ratio (CPR) 
(154,160,161). In late-onset growth restriction, these alterations in cerebral blood flow are 
associated with adverse perinatal outcomes such as neonatal metabolic acidosis, stillbirth, 
or perinatal mortality, and long-term neurological sequelae (33,162,163). In a recent meta-
analysis, however, evidence did not support routine use of CPR or MCA Doppler in 
surveillance of late growth-restricted fetuses (95). In early-onset growth restriction, these 
flow parameters are not significant predictors of outcome (142). 
Central venous circulation Doppler patterns reflect fetal right-ventricle status. Aberrations 
in ductus venosus flow—decreased, absent, or reversed flow during atrial contraction (a-
wave)—may represent myocardial impairment and increase in right ventricular afterload 
(154). Such aberrations in IUGR are associated with fetal acidemia and increased mortality 
rates (141,149). Ductus venosus indices are predictive of neonatal outcomes (15,164), and 
can predict chances of intact survival after 29 pregnancy weeks (142). Systematic reviews 
have demonstrated the moderate predictive accuracy of DV Doppler for adverse perinatal 
outcome and perinatal mortality (98,165). A recent randomized study on timing delivery in 
preterm growth restriction indicate that delaying delivery until the DV a-wave has 
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disappeared causes a small excess in stillbirths, but also a significantly improved intact 
neurologic outcome at age of two years (166). 
In placental insufficiency, fetal cerebral oxygenation is preserved if the net blood flow 
through the aortic isthmus remains antegrade (167). Retrospective and prospective studies 
have shown increased perinatal morbidity and mortality rates and suboptimal 
neurodevelopment among IUGR fetuses with abnormal aortic isthmus blood flow patterns 
(168,169). In one study of SGA fetuses with normal umbilical artery flow parameters, a 
considerable proportion had abnormal, even retrograde, blood flow in the aortic isthmus, 
demonstrating cardiovascular compromise (162). Thus, assessment of aortic isthmus 
Doppler blood flow may be of help in timing of delivery before appearance of hypoxic brain 
injury (96). 
In early growth restriction, international guidelines recommend timing of delivery based on 
Doppler velocimetry findings. With absent end-diastolic flow in the umbilical artery before 
32 GW, The Royal College of Obstetricians and Gynaecologists (RCOG) endorse delivery once 
venous Doppler findings become abnormal (119). The American College of Obstetricians and 
Gynecologists (ACOG), in turn, recommends delivery before 32 weeks, generally, in cases of 
most severe growth restriction with advanced Doppler findings such as reversed end-
diastolic flow in the umbilical artery (120). However, with pathological umbilical artery 
Doppler findings, delivery no later than 37 GW is the recommendation(119,120). In late-
onset growth restriction with normal umbilical artery Doppler, or among SGA fetuses, 
delivery is recommended between 37 and 40 GW, depending on other risk factors such as 
ACM Doppler velocimetry (119,120). 
Screening and detection of fetal growth restriction. Adverse outcomes related to fetal 
growth restriction are reduced by accurate identification of growth restriction and 
structured fetal surveillance (30). However, a substantial proportion, as high as 15% to 35%, 
of SGA neonates, are not identified by ultrasonography assessments, regardless of method 
(80,153). A routine third trimester ultrasound for fetal biometry does not improve perinatal 
outcome in low-risk populations (79).  
Placental-related fetal growth restriction arises primarily due to deficient remodeling of the 
uterine spiral arteries supplying the placenta during early pregnancy (59). Especially in 
selected risk-pregnancies, abnormal uterine artery Doppler indices predict pre-eclampsia 
and fetal growth restriction and may thus be beneficial in pregnancy management 
(119,170). Timely aspirin treatment in risk-pregnancies with abnormal uterine artery flow 
parameters may improve placental function and thus reduce risk for pre-eclampsia and 
fetal growth restriction (171). In a recent meta-analysis on first-trimester uterine artery 
Doppler, however, its specificity in predicting fetal growth restriction at any gestational age 
was high (93.3%), but its sensitivity low (15.4%) (89). 
Several placenta-originating maternal serum biomarkers such as pregnancy-associated 
plasma protein A (PAPP-A), soluble fms-like tyrosine kinase 1 (sFlt-1), insulin-like growth 
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factor-1 (IGF-1), human chorionic gonadotropin (hCG), and alpha-fetoprotein (AFP) may be 
useful in risk-assessment of pregnancy (172). 
Prevention of fetal growth restriction. Among selected high-risk pregnancies, timely began 
aspirin treatment can reduce IUGR incidence (173,174). Moreover, in such risk-pregnancies 
antithrombotic therapy with heparin has demonstrated promising results in preventing low 
neonatal birthweight (175). New treatments against pre-eclampsia, such as pravastatin, may 
prove useful in preventing associated fetal growth restriction (176). Similarly, treatments 
modulating placental circulation, like sildenafil, may improve fetal growth and maternal 
blood pressure during preeclampsia pregnancy (177). 
Impact of gestational age on pregnancy outcome 
Perinatal outcomes vary by gestational age. According to the WHO definition, preterm birth 
occurs at < 37+0 GW and post-term birth at ≥ 42+0 GW (178). The American College of 
Obstetricians and Gynecologists (ACOG) recommends a further division of term birth as 
follows: Early term (37+0 to 38+6 GW), full term (39+0 to 40+6 GW), and late term (41+0 to 41+6 
GW) (179). Additionally, preterm births are further classified by gestational length as 
extremely preterm (< 28+0 weeks), very preterm (28+0 to 31+6 GW), and moderate (32+0 to 
33+6 GW) to late preterm births (34+0 to 36+6 GW) (180). Regardless of these precise 
definitions, gestation-associated risk profiles are in fact a biological continuum. A U-shaped 
relationship between adverse pregnancy outcomes and gestational age occurs (34). The 
optimal gestational length appears to be reached between 39 and 41 completed weeks, and 
deviation from this may elevate risk for suboptimal outcomes (34).  
Preterm birth rate approximates 11% of all births worldwide, ranging from 18% in sub-
Saharan Africa to 5% in in northern Europe (181). During 2017, preterm birth occurred in 
5.9% of pregnancies in Finland (41). Neonatal morbidity and mortality are significantly higher 
among neonates born before 37+0 GW, with risks inversely correlated with gestational age 
(34). Antepartum asphyxia frequently occurs in preterm births, with up to 50% of such 
asphyxia cases moderate to severe (55). Preterm births account, worldwide, for most 
neonatal deaths (181). Furthermore, preterm birth is associated with a considerable 
economic burden (181). 
During the neonatal period and early childhood, preterm infants have elevated rates of 
temperature instability, respiratory distress, apnea, hypoglycemia, seizures, jaundice, 
kernicterus, NEC, feeding difficulties, and periventricular leukomalacia (PVL) (182). The 
frequencies of CP—as well as of intellectual and sensory disabilities—are inversely related 
to gestational age at birth, and neurodevelopmental disabilities and recurrent health 
problems require excessive rehospitalizations (182). Cognitive dysfunction such as school 
difficulties and behavioral problems may subsequently arise and continue into adolescence 
(182). Not unexpectedly, the risk for chronic health disorders appears to be higher among 
those born preterm (182). 
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Of the preterm births, those occurring after 32+0 GW—moderate and late preterm births—
comprise up to 84% (181). As compared to full-term infants, these infants born close to term 
are also physiologically immature, with limited compensatory responses. Thus, such infants 
are at increased risk for acute infectious and respiratory disorders, early childhood mortality, 
neurodevelopmental and cognitive disabilities, and behavioral problems at school age (38).  
Early-term birth, at 37+0 to 38+6 GW, occurs in high-income countries, in 17% to 27% of 
pregnancies, in Finland comprising 17% of births (183). Traditionally, studies have considered 
term births as a homogenous reference low-risk population. Recent evidence, however, 
demonstrates increased short- and long-term morbidity related to early term birth. Excessive 
neonatal admissions, prolonged hospitalizations, various health complications during early 
childhood, and developmental delay do occur among early-term infants, with considerable 
potential economic consequences (38). A significant amount of central nervous system 
growth and maturation—such as a 50% increase in cortical volume and a 25% increase in 
cerebellar development—occurs between 34 GW and 40 GW (34). One meta-analysis has 
demonstrated increased risk for CP as being related to birth at early term (34). Additionally, 
these children are at risk for a wide range of more subtle impairments such as difficulties in 
mathematics, behavioral and emotional problems necessitating medication, and social- and 
communication disadvantages (34,184). Lately, more attention has been on late preterm and 
early term birth rates, making avoidance of obstetric interventions and inductions at early 
term without medical indications the recommendation (183,185). 
Late term and post-term pregnancies comprise those pregnancies continuing beyond 41 
GW. The prevalence of post-term birth varies significantly among countries, occurring in 
European and North American countries in 0.4% to 8.1%, and its prevalence appears to be 
decreasing, along with a more active delivery induction policy (39,186). In Finland in 2016, 
the rate of post-term birth was 4% (41). During the same period, 19% of pregnancies were 
ongoing at 41+0 GW (41). 
Perinatal and delivery outcomes in pregnancies beyond term. Pregnancies beyond 41 GW are 
at increased risk for perinatal morbidity and mortality (36,37). Post-term pregnancies ≥ 42+0 
GW account for approximately 14% of stillbirths worldwide, contributing considerably to 
stillbirth rates in high-income countries, as well (12,35). Numerous studies show increases in 
perinatal mortality rates, including both stillbirths and neonatal deaths, among term 
pregnancies with advanced gestations (36,187-189). Several studies demonstrate a U-
shaped relationship between gestational age and perinatal mortality (40,190).  
Furthermore, risks for perinatal morbidity and complications are higher in post-term 
deliveries. Meconium aspiration syndrome (MAS), pneumonia, shoulder dystocia, and 
traumatic injuries occur more frequently in post-term deliveries (188). With advancing 
gestation, umbilical artery pH and oxygen partial pressure (pO2) tend to decrease, while 
acidosis, carbon dioxide (pCO2), and lactate increase (7,189,191). Among post-term 
deliveries, risks for perinatal asphyxia, seizures, and neonatal encephalopathy are 
preeminent (188,192). Long-term adverse outcomes are associated with advanced 
gestation. A Norwegian cohort study has demonstrated that intellectual performance 
 32 
declines among individuals born beyond 41 GW (193). In a Swedish cohort study, risk for 
developmental delay was higher among children born post-term (194). Additionally, 
occurrence of long-term metabolic and cardiovascular risk factors is higher among children 
born post-term (195,196). 
Maternal complications increase in deliveries beyond 40 GW as well. In post-term deliveries, 
cephalopelvic disproportion, labor dystocia, acute cesarean section, postpartum 
hemorrhage, and infections occur excessively  (188). 
Surveillance methods in post-term pregnancies. No clear cut-off gestational age exists for 
adverse outcome, and no antenatal surveillance method can entirely eliminate the risk for 
stillbirth or fetal compromise during delivery (191,197). Evidence from randomized 
controlled studies on advantages of surveillance in improving outcomes is lacking. Some 
studies suggest that fetal monitoring and routine ultrasound examination after 41+0 GW 
reduces perinatal mortality and severe neonatal morbidity, but no consensus exists as to test 
utilized or frequency of testing (198,199).  
No evidence supports any benefits of maternal fetal movement counting (189). According to 
one systematic review, biophysical-profile assessment in high-risk pregnancies, including 
post-term pregnancies, fails to improve perinatal outcomes, and may even cause an increase 
in cesarean section rates (84). Low amniotic-fluid volume frequently occurs in late-term and 
post-term pregnancies and is generally considered a marker of chronic placental 
insufficiency and reduced kidney perfusion (200). However, in post-term pregnancies, 
oligohydramnios has not predicted adverse perinatal outcome, but such observation may 
lead to more obstetrical interventions (200,201). 
Doppler assessments are unlikely to add considerable value in surveillance of late-term and 
post-term pregnancies (202). In such pregnancies, pulsatility indices of the umbilical artery, 
MCA, ductus venosus, or inferior vena cava do not differ between individuals with favorable 
and unfavorable outcomes (202-204). In uncomplicated pregnancies, beyond term gestation 
placental vascular resistance does not increase (205). Some controversy occurs as to the 
effectiveness of CPR in predicting adverse outcome in late and post-term pregnancies. Low 
CPR among pregnancies at term and beyond is associated with fetal distress and obstetric 
interventions during delivery, and with adverse perinatal outcome (206,207). The predictive 
value of CPR for adverse outcomes, however, is poor (202,207). One recent systematic 
review on term pregnancies suggests that CPR has some predictive utility and can serve as 
an adjunctive surveillance method in identifying fetuses at risk (208). 
The characteristics of cCTG evolve along with advancing pregnancy (99). Certain changes 
appear in recordings during post-term gestation such as decreasing long- and short-term 
variation, increased proportion of traces without accelerations, higher proportion of large 
decelerations, more frequent and longer episodes of low variation, and increased basal fetal 
heart rate. Fewer tracings meet the criteria of normality, than in term pregnancies (99). In 
post-term pregnancies, signs of sympathetic activity such as increased fetal heart rate and 
small accelerations, may precede fetal distress during delivery (209). However, evidence on 
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utilization of computerized CTG as improving outcomes or predicting adverse events in post-
term births is insufficient (203,210). 
Controversies regarding induction of delivery and expectant management. Agreement on the 
optimal timing of delivery is lacking. European and American guidelines recommend 
beginning the surveillance and inducing delivery variably between the 41+0 and 42+0 GW 
(211). Severe adverse events such as HIE and perinatal mortality occur infrequently in low-
risk populations, leading to considerable numbers of pregnancies needed to treat to improve 
outcomes, and to challenges in organizing studies sufficiently large to demonstrate beneficial 
effects (211). However, the number of deliveries needed to induce to avoid one perinatal 
death decreases continuously after the 41+0 GW (212).  
Recently a large RCT comprising 1801 women demonstrated that induction of labor at 41 
GW led to a lower rate of composite adverse outcomes including perinatal mortality, 
neonatal intensive care unit (NICU) admission, and Apgar score < 4 at five minutes, as 
compared to expectant management until 42 GW (213). The cesarean section rates and 
instrumental vaginal delivery rates between these groups were comparable (213). A recent 
meta-analysis on RCTs including low-risk term pregnancies with induction of delivery versus 
expectant management demonstrated a lower risk of perinatal death in the induction group, 
with the number needed to treat being 426 (95% CI 338 to 1337) (214). Furthermore, the 
rates of low Apgar scores < 7 at 5 minutes and NICU admissions, as well as cesarean-section 
rates, were lower in the induction group than in the expectant management group. 
Otherwise, maternal or neonatal complications between groups did not differ (214). An 
observational register study from Sweden showed that implementation of a more active 
induction policy post-term—from 43+0 GW to 42+0 GW—caused significant decreases in 
perinatal mortality, MAS, and low Apgar scores at birth (186). Controversial results have also 
been reported. A current register study on term deliveries utilizing propensity score method 
demonstrated increased risk for cesarean section until 41 GW, no effect on perinatal 
mortality and no low Apgar score, but increased risk for prolonged hospital stays related to 
induction of delivery (215). 
The long-term health effects of delivery induction on offspring are somewhat controversial. 
One  Danish cohort study suggests that introduction of a more active delivery-induction 
strategy to beyond-term pregnancies led to reduction in CP and in neonatal death rates 
(216). On the other hand, a Norwegian register study revealed an independent association 
between induction of labor and CP among term pregnancies (217). However, in a case-
control study on HIE at term, induction of labor was unrelated to increased risk for 
encephalopathy (8). Induction or augmentation of delivery is associated with increased rates 
of autism spectrum disorders, especially among male children (218). The optimal 
management of pregnancies beyond 41+0 GW is still debated and further studied, since the 
absolute risk for adverse perinatal outcomes is low regardless of management or induction 
protocol (211,213). 
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Antenatal neuroprotection 
Placental dysfunction leading to intrauterine hypoxia and growth restriction may necessitate 
preterm delivery. Prematurity is associated with increased risk for neurologic impairments, 
most frequently CP and cognitive dysfunction, such as intellectual impairment or 
developmental delay (219). While more delicate impairments like learning difficulties are 
included, preterm neonates are at 28% risk for developing at least one long-term 
complication and at 8% risk for multiple impairments (220). With earlier gestations, the risks 
for sequelae are greater. Fetal neuroprotection aims to prevent these adverse outcomes.   
Magnesium sulphate (MgSO4) treatment for fetal neuroprotection, conferred to women at 
risk of preterm delivery before 30 to 32 GW, is associated with reduction in CP risk by 32%, 
along with a significant reduction in gross motor dysfunction rate (221). Antenatal 
magnesium treatment reduces all cases of CP, but also of moderate and severe CP alone 
(219). This effect is unassociated with any reduction in intraventricular hemorrhage- or cystic 
PVL rates (219). Magnesium neuroprotection does not result in increased perinatal mortality 
nor give rise to significant short- or long-term maternal or neonatal morbidities (219). 
Although details of the neuroprotective mechanism of magnesium are unknown, they 
appear to be complicated and related to treatment of timing (70,222). Its beneficial effect is 
independent on prematurity etiology (219). Recently, magnesium neuroprotection was 
included in several national guidelines and WHO recommendations (180).  
Antenatal corticosteroid treatment is routine management in accelerating fetal lung 
maturation among women at risk for preterm delivery. In addition to improving lung 
development, treatment leads to a reduction in perinatal and neonatal death, NEC, need for 
mechanical ventilation, systemic infections, intraventricular hemorrhage, and PVL rates 
(220,223,224). Antenatal glucocorticoids probably enhance maturation of fetal 
cardiovascular responses to hypoxia, as well (2).  Several randomized studies on antenatal 
corticosteroids among preterm births below 36 GW show a resultant decrease in CP rates 
(223), although a recent meta-analysis could not confirm this finding (72). Nevertheless, 
based on these data, in preterm neonates, corticosteroids appear to be neuroprotective. 
However, the role of antenatal corticosteroid treatment and subsequent hyperglycemia in 
context of asphyxia or HIE is unclear (70). 
Emerging antenatal neuroprotective treatments against developing brain injury are under 
intensive study. Progesterone has shown potential neuroprotective benefits in animal 
models of birth asphyxia and in reducing inflammation and improving myelination (220). A 
recent meta-analysis failed to demonstrate a clear reduction in CP rates with progesterone 
treatment in prevention of preterm birth, however (72). Melatonin has multiple endogenous 
functions. It has demonstrated neuroprotective effects in animal models, probably due its 
antioxidative and cytokine-modulating features (220). Several other agents, such as creatine 
and allopurinol, may also have neuroprotective features when administered antenatally (72). 
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ADAPTATION AT BIRTH 
Transition from fetus to newborn and adaptation to extrauterine life is a complex process, 
requiring rapid changes in most vital functions (4). 
Physiological changes at normal birth 
The first and most critical adaptations concern cardiovascular and pulmonary systems (225). 
Pulmonary vascular resistance decreases markedly by oxygen exposure at the first breaths 
(4). After fetal levels of 60%, neonatal oxygen saturation rapidly rises over 90% (4). After 
placental separation, on the other hand, systemic vascular resistance increases. These 
changes together lead to the closure of fetal circulatory shunts. Cardiac output and blood 
flow to the lungs, heart, kidneys, and intestines increase (4,225). Surfactant secretion into 
the fetal alveoli and fluid clearance from the lungs begin during the delivery process and are 
generally completed within two hours after birth (4). 
Metabolic and endocrine changes occur at transition in order to maintain blood pressure, 
blood glucose, and free-fatty-acid levels (4). During normal birth, the HPA axis is activated, 
leading to substantial increases in production and in release of catecholamines, renin-
angiotensin, and vasopressin. This is important in regulation of a wide variety of functions, 
such as in reducing insulin levels, raising liver glucose production, stimulating lung-fluid 
resorption, maintaining water homeostasis, and modifying the hemostatic system and 
nociception during the adaptation process (4,53,226). Hematologic changes include 
decreased production of fetal hemoglobin and decreased secretion of EPO, resulting in 
reduced erythropoiesis in neonates (4). 
Effect of delivery mode on adaptation 
During normal birth, the endocrine stress response is activated, with the mode of delivery 
strongly affecting these responses. Several hormones such as ACTH, corticotropin-releasing 
factor, cortisol, adrenalin, noradrenalin, β-endorphin, and vasopressin are significantly lower 
among neonates born by primary cesarean section than by vaginal delivery (53,226,227). 
This can inevitably affect neonatal adaptation processes and may even have a long-term 
impact on neurologic development and health (228). Fetal distress and assisted vaginal 
delivery can further enhance the stress response. 
Pulmonary adaptations, for instance, are triggered during delivery, and liquid absorption is 
enhanced by β-receptor-agonist stimulation throughout normal delivery process (4). Primary 
cesarean section is associated with increased risk for respiratory morbidity. Among term 
infants born via primary section, the incidence of transient tachypnea and RDS are double 
the incidence of those via vaginal birth (225). Furthermore, physiologically increased levels 
of AVP support water homeostasis after birth. Water loss, and consequently weight loss, is 
more pronounced after primary cesarean than after vaginal delivery (53). 
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Challenges in neonatal transition 
A considerable proportion of neonates, up to 10%, require some clinical intervention at birth 
for facilitating the transition (225). Approximately 1% need extensive resuscitation (225).  
Several circumstances, such as gestational age at birth, maternal health conditions, and 
pregnancy and delivery complications, affect the neonatal transition stage. Chronic 
intrauterine hypoxia changes catecholamine regulation and fetal sensitivity to 
glucocorticoids and can interrupt adaptive mechanisms at birth, as well as affect long-term 
metabolism (1). Perinatal hypoxia and asphyxia suppress initiation of breathing in term and 
preterm births (4). Persistent pulmonary hypertension of the newborn is a severe neonatal 
condition with continuously elevated pulmonary vascular resistance and extrapulmonary 
shunting, leading to neonatal hypoxia (225). Increased risk for this disorder is associated with 
both post-term and late preterm births (225). Preterm infants are more prone to pulmonary 
complications due to this relatively lower lung volumes and immature lung-fluid clearance 
mechanisms (225). Furthermore, the antioxidant defense system is immature until late 
gestation and predisposes preterm infants to damage caused by relative oxidative stress at 
birth (229).  
Most neonates cope well with adaptations required by the transition to extrauterine life, but 
clinicians caring for neonates should be aware of the risks and prepared to provide timely 
treatment if necessary (225). 
PERINATAL ASPHYXIA 
In asphyxia, impairment of respiratory gas exchange leads to tissue hypoxia and 
accumulation of lactic acid, resulting in metabolic fetal acidosis. Such condition further 
deteriorates accompanied by reduced clearance of carbon dioxide (5,60). 
Mechanisms of asphyxia 
Short-term accumulation of carbon dioxide— isolated respiratory acidemia—is quickly 
reversible and cause no fetal injury (78). Prolonged hypoxia, however, shifts the cellular 
energy metabolism towards anaerobic processes. The increased amount of intracellular 
hydrogen ions eventually leads to depletion of buffering mediators. Consequently, base 
deficit increase and metabolic acidosis arise, predisposing the fetus to tissue injury (78). 
Intrapartum aberrations and complications may affect placental function and fetal 
oxygenation. The most common cause of fetal hypoxia and acidosis is excessive uterine 
contractile activity during delivery (100). Maternal complications such as respiratory distress, 
cardiorespiratory arrest, sudden hypotension due to aortocaval compression or after 
epidural or spinal analgesia, placental abruption and uterine rupture, can interrupt fetal 
oxygenation. Other less frequent complications leading to hypoxia and acidosis are umbilical-
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cord complications, fetal hemorrhage, shoulder dystocia, or retention of the after-coming 
head in a breech delivery (78). 
Fetuses suffering from intrauterine hypoxia are more susceptible to adverse intrapartum 
events. Perinatal asphyxia originates during the antepartum period from underlying chronic 
maternal or fetal conditions in approximately 50%, whereas during delivery occur 40%, and 
in the early postnatal period 10% (10,230). However, in term pregnancies, the majority of 
fetal asphyxia cases occur in pregnancies without known antepartum risk factors (5). 
Consequently, pregnancies at zero risk for intrapartum fetal asphyxia do not exist (231).  
Incidence and consequences of asphyxia 
Perinatal asphyxia requiring significant resuscitation at birth occurs in high-income countries 
in approximately 20/1000 to 25/1000 live births (5,232). In preterm births, asphyxia occurs 
even more frequently, in 73/1000 births, and it is moderate or severe in half of the cases 
(55). Globally, neonates suffering from birth asphyxia annually amount up to four million (9). 
Asphyxia is the second most frequent cause of death within the first 28 days, contributing 
up to 10.5% in children younger than 5 years (233). Furthermore, it is estimated to contribute 
to millions of antepartum and intrapartum stillbirths worldwide, and an equal number of 
children develop permanent neurologic sequelae such as CP, epilepsy, intellectual disability, 
and sensorineural impairments (9,12). In the literature, some inconsistency exists among 
definitions of asphyxia, studies reporting highly variable rates of adverse outcomes among 
asphyxiated neonates, severe deficits occurring in 5% to 100% (10). 
HYPOXIC ISCHEMIC ENCEPHALOPATHY (HIE) 
Owing to efficient compensation mechanisms, the majority of the neonates exposed to 
perinatal asphyxia will recover without developing long-term sequelae. Constant severe 
metabolic acidosis eventually results in, however, a vital-organ and cerebral-injury cascade, 
leading to neonatal HIE (10,11). Globally, HIE incidence varies between countries parallel 
with neonatal mortality rates, occurring in low-mortality countries in 1-3/1000 live births and 
in countries with a high neonatal mortality rate in 12/1000 (70,116). Among term neonates, 
HIE incidence approximates one to three cases per 1000 births (234). However, a recent 
cohort study suggested that the HIE rate among preterm neonates is considerably higher, up 
to 37 cases of moderate to severe HIE per 1000 (235). 
Definition and diagnosis 
The clinical definition of encephalopathy consists of disturbed neurologic function in a 
neonate born beyond 35+6 GW (22). Manifestations of this condition are subnormal level of 
consciousness or seizures, difficulty with initiating and maintaining respiration, hypotonia 
and depressed reflexes, abnormal oculomotor or pupillary movements, and weak or absent 
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sucking (22). Several mechanisms, ones such as birth asphyxia and intrapartum events, 
metabolic and genetic disorders, congenital neurologic conditions, infections, and 
medications, can contribute to neonatal encephalopathy and consequent neurologic 
impairment. Brain injury can occur during pregnancy or in the neonatal period at multiple 
points. Neonatal hypoxic ischemic encephalopathy (HIE) specifically refers to the neurologic 
implications of perinatal asphyxia (22).  
Approximately 50% to 80% of neonatal encephalopathy is of hypoxic ischemic origin (11). A 
careful assessment to determine etiology and identify these neonates is essential, since 
these neonates can significantly benefit from timely action and intensive care treatment 
(11). Certain findings, such as low Apgar score of < 7 at 5 and 10 minutes, arterial cord blood 
pH < 7.0 and BE < -12, and early imaging evidence of cerebral edema, indicate the probability 
of an intrapartum hypoxic event as the origin of neonatal encephalopathy (22,78). Evidence 
of peripartum hypoxic events and severe delivery complications such as placental abruption 
or abnormal fetal heart tracings generally help in identifying affected neonates, but the false-
positive rate in CTG is high, and predictive patterns are usually evident only during the final 
hours before birth (8,231). HIE diagnosis is based on clinical manifestations, imaging, and 
electrophysiological monitoring (20). The most sensitive method in neonatal encephalopathy 
is magnetic resonance imaging (MRI); nevertheless, the full extent of the defect is not 
evident until a week after the injury (22). 
Brain injury patterns in HIE 
Following hypoxic ischemic insult, neuronal injury proceeds in phases (70,236-238). The 
acute neuronal injury occurs due to disruption of the oxygen and energy supply to the brain. 
Loss of integrity of the neuronal-cell membrane leads to widespread depolarization, cerebral 
edema, and primary neuronal death (238). A latent period of approximately 6 hours follows 
the acute injury, during which, some neuronal cells recover. Subsequently, a secondary 
phase of delayed cell death occurs. Due to failure of mitochondrial function, energy and 
oxidative metabolism deteriorate. Oxidative stress and inflammation, along with reperfusion 
injury by toxic neurotransmitters from damaged brain areas, result in additional neural cell 
death (70,238). A considerable portion of the brain injury and neuronal loss occurs during 
this secondary phase. Additionally, seizures frequently appear at this phase of injury (237). 
After initial injury in severe HIE, progressive evolution of cell death occurs over hours and 
days (70). Subsequently, 3 to 4 days after the initial event, the tertiary phase of continuing 
injury arises. This phase can last from weeks to years and is characterized by chronic 
inflammation and by epigenetic changes which affect neuronal repair and reorganization 
(70,238). Associative infections and inflammation may exacerbate the extent of the injury 
and may impair treatment effectiveness (11). 
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Staging of HIE 
Severity of consequences in HIE depends mostly on the degree of the encephalopathy 
(10,239). The widely applied original Sarnat system divides the grade of encephalopathy into 
three stages (116,239). Stage I is the mildest. In this stage, neonates characteristically 
demonstrate generalized sympathetic tone and hyper-alertness with excessive deep-tendon 
reflexes. In Stage II, generalized parasympathetic tone occurs, along with strong distal flexion 
and mild hypotonia. Additionally, seizures frequently appear. Stage III is the most severe 
form of encephalopathy with clinical signs of remarkably decreased level of consciousness 
or coma, soft tone, decreased deep-tendon reflexes, and clearly abnormal 
electroencephalography (EEG) (78,116). Other ways of staging proposed include the widely 
implemented modified scoring system by Thompson; this is simple and accurate, a clinically 
applicable method for evaluating and monitoring neurologic signs and predicting outcomes 
in asphyctic neonates (24). 
Clinical consequences 
HIE is associated with high risk of neonatal death or neurodevelopmental impairment. 
Approximately 15% to 20% of affected neonates die during their first 28 days, and up to 25% 
of those who survive suffer from permanent neurological sequelae (240,241). HIE can lead 
to wide range of neurologic impairments from subtle cognitive and behavioral problems to 
severe sensorineural and intellectual disability, epilepsy, and CP (11,116). The severity and 
location of damage is influenced by degree and duration of the insult, and by developmental 
maturity of the brain (242). Preterm fetuses tolerate longer periods of hypoxia, 
hypoperfusion, and hypotension without permanent brain and organ injuries (70). On the 
other hand, late preterm neonates between 34 and 36 GW are especially vulnerable to 
ischemic events due to the extensive growth phase of their central nervous system during 
this period (19). Severity of multisystem organ dysfunction does not necessarily correlate 
with grade of brain injury, and can affect cardiovascular, pulmonary, gastrointestinal, renal, 
metabolic, and hematological systems (22,78). 
The diagnosis and prognosis of neonatal HIE is presently based on clinical signs and 
symptoms, radiologic imaging, and electrophysiological monitoring (20). The traditional 
Sarnat Score is considered valuable in estimating outcomes at mild and severe stages. Most 
neonates with stage I mild encephalopathy develop no major long-term neurologic 
impairments. Outcomes among neonates with stage II moderate encephalopathy are more 
challenging to estimate, although risk of long-term sequelae or death is increased, affecting 
up to 20% to 30% of these neonates (240). In severe stage III encephalopathy, most of the 
affected neonates either die or develop major long-term neurological sequelae such as CP 
and intellectual disabilities (19). 
Perinatal events are associated with approximately half the cases with CP (243). Most 
children with CP—from 50% to 60%— are born at term (72). In 10% to 20% of these children, 
the etiology is related to acute HIE (78,243). Rates of CP subsequent to HIE range from 10% 
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to 13% among survivors of moderate to severe encephalopathy. In particular, CP of the 
spastic quadriplegic or dyskinetic type is associated with intrapartum asphyxia and HIE at 
term (78). Sensorineural defects such as hearing loss and visual function abnormalities are 
increased in neonates with HIE (11). Furthermore, long-term impairments associated with 
HIE involve memory function, learning, and behavioral and neuropsychiatric development 
(11). Studies have reported negative effects of Stage I HIE on behavioral functions at the age 
of 9 to 10 years (18). Even mild stages of neonatal encephalopathy may thus be associated 
with long-term adverse outcomes affecting daily life (18). Importantly, a substantial 
proportion of neurologic impairments are hidden until later in childhood (244). 
NEONATAL OUTCOME MEASURES 
An unequivocal marker for predicting neonatal outcome after perinatal asphyxia and 
subsequent HIE is lacking. Only a small proportion of the neonates with evidence of 
intrapartum asphyxia will develop severe neurological impairments (245). All methods 
presently used, as acid-base balance, clinical examination including Apgar score, radiologic 
imaging, and electrophysiology have certain limitations. Nevertheless, along with the 
introduction of potent neuroprotective treatments such as therapeutic hypothermia, the 
importance has risen to swiftly and surely identify those neonates who could benefit from 
interventions. Novel biological and physiological prognostic markers are emerging, but the 
current “traditional” indicators remain valuable tools in evaluation of neonates during the 
first postnatal hours. 
Current asphyxia markers 
Acid-base balance quantified from the umbilical artery at birth presents the oxygenation 
status of neonate and may reveal fetal hypoxia and metabolic acidosis during birth (78). 
Acidosis is an early sign of fetal distress during delivery. Uterine contractions, even during 
normal vaginal birth, cause mild intermittent hypoxia and consequent respiratory acidemia, 
leading to a slight decrease in pH and an increase in pCO2 (246,247). 
Metabolic acidosis is defined as umbilical artery pH below 7.00 and base deficit (BD) above 
12 mmol/L (21,78,248). However, a continuum exists that shows increasing risk for 
encephalopathy along with deepening acidemia (21,22). Serious adverse outcomes such as 
neonatal encephalopathy, seizures,  low 5-minute Apgar scores, neonatal unit admission, 
and death begin to increase with pH values below 7.10 and BE values below -10 mmol/L 
(21,78). Umbilical artery pH less than 7.00 raises the risk for abnormal outcome in up to half 
the affected neonates (245).  Maintenance of cardiovascular adaptations and defense 
mechanisms deteriorates in severe acidemia with arterial pH < 7.05, predisposing the fetus 
to brain injury (2). One meta-analysis demonstrated an association of low umbilical artery 
pH with increased neonatal mortality, HIE, intraventricular hemorrhage, PVL, and CP (249). 
Metabolic acidosis can be identified by umbilical artery lactate concentration (78). Umbilical 
artery lactate values beyond 10 mmol/L are associated with short-term neonatal adverse 
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outcomes, and children with elevated lactate values in their scalp samples tend to be at 
increased risk for fine motoric and cognitive dysfunction at age four years (247,250). The 
positive predictive value, sensitivity, and specificity of acidosis at birth in predicting brain 
injury is, however, low (11,245). Even in severe metabolic acidosis at birth, the majority of 
neonates will be free of neurologic complications (78). 
Apgar score is a standardized tool for assessment of neonatal condition immediately after 
birth and is an important indicator of need for resuscitation (251). This scoring system 
evaluates vital cardiovascular, pulmonary, and neurologic functions by five distinct 
components: color, heart rate, reflexes, muscle tone, and respiration (78,251). Numerous 
factors affect Apgar score assessment. It is a subjective estimation and therefore 
predisposed to interobserver variability, and moreover is dependent on the neonate’s 
physiologic maturity and congenital malformations, as well as on maternal medications 
(251). Thus, low Apgar score alone is not a specific marker of intrapartum distress. 
Furthermore, in cases of hypoxia, Apgar score is depressed only when hypoxia is severe and 
prolonged (78).  
Apgar score cannot serve in predicting individual adverse neurologic outcome (251). As a 
prognostic marker of asphyxia and HIE outcomes, Apgar score has low sensitivity and 
specificity (245). Up to 80% of neonates with Apgar score ≤ 7 at 5 min will have a normal 
outcome (11,245). However, population-based studies demonstrate an increased risk for CP 
and mortality among neonates with a low Apgar score of < 5 at 5 and 10 minutes of age 
(22,78). Especially the change in score between 1 and 5 minutes represents the response of 
the neonate to resuscitation, and the degree of prolonged Apgar abnormality correlates with 
risk for neurological disability (22). In one Norwegian cohort study, low Apgar score at 5 
minutes strongly associated with CP, with 10% to 17% of the children with an Apgar score 
less than 4 developing such a condition (252). A recent cohort study from Sweden 
demonstrated an inverse association of Apgar score at 5 and 10 minutes with risk for epilepsy 
and CP among term pregnancies (253). Low Apgar score < 7 at 5 minutes is associated with 
increased risk for respiratory distress, need for assisted ventilation or intubation, NICU 
admission, and HIE (254). Among neonates suffering from asphyxia, Apgar score at 5 minutes 
predicts HIE and amplitude-integrated electroencephalography (aEEG) abnormalities (255). 
A large register-based study on more than a million live births demonstrated an association 
of low Apgar score at 5 minutes with increased risk for neonatal and infant death, the 
strongest association appearing at term (256). 
Clinical examination and neurologic estimation of the newborn are affected by medication, 
treatment, and resuscitation. Modified Apgar systems, ones involving also neonatal maturity 
and interventions, may be more sensitive and specific in predicting birth asphyxia and severe 
adverse neurologic outcomes, than is the conventional Apgar score system (23). The Sarnat 
Score system provides a summary score for describing neonatal outcome within 24 hours 
after birth (239). This system is useful in predicting outcome at mild and severe grades of 
encephalopathy (240). Outcomes of neonates with moderate encephalopathy are, however, 
more challenging to predict (240). Furthermore, neurological status may evolve—either 
improve or deteriorate—during the first days after birth, and again, treatment and 
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interventions affect assessment (240). Up to 15% to 20% of neonates with an initial grading 
of mild HIE later turn out to show more severe encephalopathy (18). Improved standardized 
methods reduce interobserver differences, and modified methods may better take the 
evolving nature of HIE into account (257,258). Nevertheless, a significant correlation exists 
between neurologic outcome at 2 years of age and Sarnat score at 24 hours, as well as with 
clinical examination at discharge from hospital exists (240). Similarly, the predictive values 
of the Thompson score system for neurologic outcome at one year are remarkable, 
particularly when the highest score and prolongation of abnormal signs are combined (24). 
Electrophysical monitoring by continuous multichannel electroencephalography (EEG) is 
nowadays the gold standard in assessing brain function and grading neonatal 
encephalopathy (11). Amplitude-integrated EEG (aEEG) is a feasible and user-friendly 
technique for assessing high-risk neonates (259). Its interpretation is based on pattern 
recognition and is in good accordance with standard EEG (259). Among neonates with HIE, 
aEEG assessment 3 to 6 hours after birth consistently predicts neurodevelopmental outcome 
at the age of one year (259). The outcomes are strongly related to the severity of EEG 
abnormalities (11). A normal or slightly abnormal EEG at 6 hours of age predicts normal 
neurodevelopment at the age of 2 years (260). Because EEG findings tend to subsequently 
improve, poor outcomes are predictable among individuals with continuously abnormal 
recordings (260). Interventions such as therapeutic hypothermia affect evolution of EEG 
patterns in HIE and consequently influence its prognostic ability (11). 
Severe fetal acidemia predicts early onset of the neonatal seizures frequently occurring in 
moderate and severe HIE (11,261). In detecting such seizures, multichannel EEG is essential, 
since aEEG alone fails to detect low-amplitude seizures (11).  Occurrence of seizures after 
perinatal asphyxia considerably affects neonatal outcome. Persistent electrographic seizures 
are associated with brain injury and correlate with poor long-term neurodevelopmental 
outcomes (262-264). 
Neuroradiology – brain imaging – has advanced significantly during recent decades. Still the 
first-line method in imaging neonatal brain is, however, cranial ultrasonography (265). It is 
valuable in screening those neonates admitted to the NICU during the first days of life and 
can be useful in differential diagnosis of encephalopathy and congenital brain abnormalities 
(265,266). Furthermore, certain neonates cannot be transferred from the NICU for further 
imaging. Currently, MRI, including diffusion weighted MRI, is considered the most sensitive 
modality and the method of choice in imaging HIE (266). A combination of imaging modalities 
such as cranial ultrasonography and MRI during the first days, prove of use to differentiate 
between perinatal injury and antenatal injury (266). Brain-imaging techniques may also 
prove useful in predicting the outcome after HIE. Alterations in Doppler parameters such as 
increase in cerebral blood-flow peak velocities, have demonstrated predictive value for one-
year neurologic outcomes among asphyxiated newborns (267). Injuries may, however, not 
be visible until 24 hours or more after the insult; the injury’s full extent may be evident only 
7 to 21 days afterward (22,259). 
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Figure 3. Widespread hypoxic ischemic encephalopathy injury in neonatal MRI: Bilateral 
restricted diffusion in frontal cortical and subcortical areas, along with watershed 
areas. Signal changes in corpus callosum, thalami, and basal ganglia. By author 
Novel markers in the prediction of the outcome 
More precise and earlier markers for diagnosing and predicting the outcome of HIE are 
crucial. The best method may be a combination of several consistent markers such as 
physiological, neuroradiological-, and biomarker-assessment composed together (11).      
Advances in neuroradiology have enhanced understanding of the mechanisms and timing 
of brain injury (266). Improvements in MRI have confirmed that certain injury patterns in HIE 
are of prognostic and diagnostic value and have aided in development of treatments such as 
hypothermia timing (266). In HIE, novel MRI techniques may serve as biomarkers of 
neurodevelopmental outcome (266). Proton MR spectroscopy (1H-MRS) is specific and 
sensitive in identifying the lesions, and a potent predictor of outcome after HIE (268). After 
HIE, novel quantitative MRI techniques such as diffusion tensor imaging tractography and 
arterial spin labeling predict cognitive and motor outcome (269,270). Some limitations, such 
as correct timing of imaging and influence of treatment on findings, affect the prognostic 
value of neuroradiologic modalities, as well (266). 
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Heart rate variability (HRV) describes the parasympathetic and sympathetic control of heart 
rate and is easily and non-invasively measured by routinely recorded electrocardiogram 
(ECG) (271). Abnormalities in heart rate variability are associated with pathological EEG and 
MRI findings, and reduced HRV may show potential in assessment of HIE grading and 
prediction of long-term outcomes (271,272). 
Biomarkers are one focus of this active research field, especially biomarkers with the 
potential to predict neurodevelopmental outcome. Currently, no definitive blood biomarker 
of HIE is in clinical use, but several novel biomarkers have demonstrated promising 
diagnostic and prognostic features in pilot studies (11,19,273). Some of these biomarkers, 
ones such as interleukins IL-6 and IL-6, and activin-A, are, in HIE, significantly elevated in the 
umbilical cord blood already at birth (11), while other markers like neuron-specific enolase 
(NSE) and protein S100B rise after a slight delay following the initial insult (11,273). The basis 
of utilization of these biomarkers is diverse. Some biomarkers are related to inflammation, 
because cytokine and chemokine levels vary according to the phase of the injury and of the 
recovery processes (20). Specific neurobiomarkers such as glial fibrillary acidic protein 
(GFAP), NSE, protein S100B, and Tau, are principally brain constituents which are measurable 
in biological fluids in relation to HIE (19). Additionally, vasoactive agents like adrenomedullin, 
hematopoiesis-regulating hormone EPO, and markers of tissue damage evaluated in other 
situations (such as troponin and copeptin in cardiac distress in emergency departments) are 
potential prognostic markers for HIE (19,20,48,49,274). Studies have demonstrated 
significant alterations in metabolomics and transcriptomics among neonates with perinatal 
asphyxia and HIE, and these may have diagnostic value (11). In addition to blood, other 
biological fluids such as cerebrospinal fluid, urine, and saliva are potential targets for 
biomarker evaluation. Even maternal blood samples can be of use to detect increased risk 
for HIE, since quantification of circulating microRNAs can reveal fetal hypoxia during 
pregnancy and delivery (275). 
The objective is that a biomarker, or a combination of markers, could be assessed quickly 
and easily at certain time-intervals to screen for brain injury, to identify neonates suitable 
for neuroprotective intervention, to monitor the progression of disease, and to provide 
reliable short- and long-term prognoses (11,19,20). 
NEONATAL NEUROPROTECTION 
HIE is a major problem globally, causing a vast humane and economic burden for patients, 
families, and society. It is associated with high mortality, with death rates among affected 
neonates from 10% to 60%. Furthermore, at least a quarter of those who survive develop 
severe neurodevelopmental sequelae (237). HIE, being the single most common contributor 
to disability worldwide, accounts for 10% of all disability-adjusted life-years (116). Thus, 
effective neuroprotective prophylactic actions and treatments are urgently needed. 
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Therapeutic hypothermia 
Nowadays, is therapeutic hypothermia the treatment of choice for HIE in term and near-
term neonates (13,14). The time-window for therapeutic interventions occurs during the 
latent phase following the primary hypoxic ischemic insult, before the secondary injury 
begins. Introducing therapeutic hypothermia as a neuroprotective treatment has improved 
the prognosis of moderate and severe encephalopathy significantly (244). A meta-analysis of 
RCTs has clearly demonstrated that therapeutic hypothermia in term- and late-preterm 
neonates with moderate to severe HIE reduces death and major neurodevelopmental 
disability among survivors at 18 or 24 months of age, with an absolute risk reduction of 15%, 
when initiated within 6 hours after birth (237). Especially important, therapeutic 
hypothermia significantly reduces CP. Neonates with moderate encephalopathy seem to 
benefit more from hypothermia than those with a severe condition. Notably, therapeutic 
hypothermia improves survival without increasing severe impairments (237). Studies on 
long-term outcomes after therapeutic hypothermia are still ongoing, but, some follow-up 
studies, such as the Total Body Hypothermia for Neonatal Encephalopathy Trial (TOBY), have 
demonstrated promising neurodevelopmental outcomes at age six to seven years:  a 
significantly larger proportion of children in the hypothermia group than in the control group 
survived without neurologic impairments (45% vs. 28%, RR 1.60; 95% CI 1.15 to 2.22) (244). 
Furthermore, hypothermia-treated children had less CP (21% vs. 36%, p=0.03) or moderate 
or severe disability (22% vs. 37%, p=0.03) than did their control group. However, despite 
improvements in therapeutic intervention, of treated neonates with moderate or severe 
encephalopathy, up to 25% still die, and of survivors, 20% suffer from sensorimotor and 
cognitive impairments (244). 
Patient selection and indications for therapeutic hypothermia. Therapeutic hypothermia is 
recommended for neonates at or beyond 36 GW with moderate to severe HIE, especially in 
areas and countries with abundant resources (276). The criteria for hypothermia should be 
in accordance with protocols published in large trials including evidence of acute hypoxic 
ischemic event, such as Apgar score ≤ 5 at 10 minutes, resuscitation ≥ 10 minutes, or severe 
acidosis - pH < 7.0 or BE ≤ 16mmol/L - within one hour after birth (276,277). Clinical signs of 
moderate to severe encephalopathy should include at least three abnormal neurologic signs 
concerning either level of consciousness, spontaneous activity, posture, tone, primitive 
reflexes, or the autonomic nervous system, and aEEG may assist in diagnosing the severity 
of encephalopathy (24,277). Therapeutic hypothermia should be initiated within the first 6 
hours of birth and last for 72 hours (277). The therapeutic-hypothermia time window is 
narrow, and currently the enhancement of neurodevelopmental outcomes seems to require 
diagnosis and initiation of hypothermia after birth to occur earlier (14). However, considering 
the evolving nature of HIE, the existing indicators are limited, and the grading is not 
consistent during the first 6 h of life (14,18). 
Neonates with mild HIE comprise 50% of the affected cases and are generally considered a 
low-risk group (278). However, in a recent meta-analysis, up to 25% of neonates initially 
diagnosed with mild HIE have had an abnormal outcome defined as CP, death, or later poor 
performance on standardized neurodevelopmental tests age 18 months or older (278). 
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Consistently, adverse cognitive and neuromotor findings occurred in a study on long-term 
outcomes at age 5 years, with survivors of mild HIE demonstrating cognitive outcomes 
similar to those of children with moderate encephalopathy without hypothermia treatment 
(279). Unfortunately, among neonates with mild or no encephalopathy, the predictive value 
of any abnormal neurologic sign is extremely poor, with positive predictive values for adverse 
outcomes ranging from 0% to 54% (18). 
The balance of risks and benefits of therapeutic hypothermia for mild HIE is unclear. 
Treatment of all the cases would promote possible adverse effects such as cardiac 
dysfunction, arrhythmias, coagulopathy, thrombocytopenia, leukocyte dysfunction, and 
pulmonary hypertension, as well as invasive treatment, delayed oral feeding, and separation 
from families (14,237). New strategies, perhaps biomarkers, are essential for optimal 
assessment of neonates with HIE, and for selection of patients suitable for such therapeutic 
interventions.  
Novel emerging therapies 
Although therapeutic hypothermia has improved outcomes after moderate and severe HIE, 
in clinical trials, despite the despite the hypothermia treatment, neonates who still die or 
suffer from disabilities such as CP, intellectual impairments, and epilepsy, may reach 40% to 
45% (241,280,281). Additionally, some neonates in need of neuroprotection have no access 
to therapeutic hypothermia. Preterm neonates and neonates with mild HIE are not currently 
eligible for hypothermia, and the safety and efficacy of therapeutic hypothermia for HIE in 
low- and middle-income countries is still to be established (241). Thus, adjunctive 
neuroprotective therapies are necessary. 
Ongoing studies aim at developing low-cost and easily available supplementary and 
alternative neuroprotective therapies to improve neonatal outcomes worldwide. Several 
promising options, both exogenous agents and agents based on endogenous induction of 
protective mechanisms, are currently in focus (14,282).   
Recombinant erythropoietin (rEPO) is one of the most promising neuroprotective agents. In 
addition to regulating erythropoiesis, EPO has potential neuro‐, cardio‐, and 
nephroprotective effects, as well as beneficial effects on wound healing (283). EPO 
modulates injury response by receptor-mediated cell-specific action and by non-specific 
effects. EPO’s anti‐apoptotic, anti-inflammatory, antioxidative, anti-excitotoxic, and 
cytoprotective features contribute to neuroprotection. Furthermore, EPO promotes the 
proliferation, maturation, and differentiation of oligodendrocytes and neurons, and 
activates the neurogenesis and angiogenesis essential for injury repair processes (14,284). 
Thus, EPO may improve neurologic outcomes by acutely reducing brain injury, and by 
promoting long-term beneficial effects for neuronal repair and regeneration (281). 
Exogenously administered recombinant EPO has demonstrated neuroprotective effects plus 
the ability to reduce the amount of damage in the brain after hypoxia (285-287). 
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In preterm neonates, exogenous EPO is currently utilized to reduce the need for red cell 
transfusions (288). A recent meta-analysis on erythropoiesis-stimulating agents in preterm 
neonates suggests that in addition to reducing rates of red blood cell transfusions, early 
administration of erythropoiesis-stimulating agents significantly reduces rates of IVH grade 
III and IV, PVL, and NEC (288). Mortality rates were unaffected. Early EPO treatment 
appeared to reduce brain damage by reducing neurodevelopmental impairment at age 18 to 
22 months, but the results in individual studies were conflicting (288). In a randomized study 
of 800 preterm neonates under the age of 32 GW, among neonates in the rEPO treatment 
group, incidences of IVH, PVL, NEC, and sepsis fell (289). Additionally, the rate of moderate 
to severe neurological disability at 18 months of corrected age was significantly lower in the 
EPO group than in the placebo group (7% vs. 19%, p < 0.001) (289). No difference in adverse 
events, such as thrombosis, hypertension, polycythemia, or retinopathy of prematurity 
occurred (289). However, another study comprising 450 preterm neonates failed to 
demonstrate any improvement in short-term outcomes including retinopathy of 
prematurity, IVH, sepsis, NEC, enterocolitis, bronchopulmonary dysplasia, and mortality 
after rEPO treatment as compared to the placebo-treated group (290). Confirmation of the 
advantages of EPO treatment in preterm neuroprotection requires further studies. 
EPO treatment as monotherapy has improved neurologic outcome also in several studies on 
term neonates with HIE. A small case-control study on neonates with mild to moderate HIE 
demonstrated reduced blood NO concentrations and improved electroencephalographic 
findings at 2 weeks of age, and fewer neurodevelopmental abnormalities at 6 months among 
neonates treated with EPO as compared to findings in neonates receiving conventional care 
(291). Two randomized studies on moderate to severe HIE found no effect on mortality from 
EPO therapy (292,293). Nevertheless, the first study indicated an improvement in long-term 
neurologic and developmental outcomes at 18 months among infants with moderate HIE in 
the EPO treatment group (292). The more recent study demonstrated, at 19 months of age 
in the EPO monotherapy group in both moderate and severe HIE, compared to children in 
placebo group, decreased risks for CP  and need for anticonvulsants, and fewer brain 
abnormalities in MRI (293). 
Because therapeutic hypothermia is the standard HIE treatment, adjuvant neuroprotective 
treatments during hypothermia may lead to further improvements in outcomes. A phase-II 
randomized trial for neonates with moderate-to-severe HIE examined rEPO as an adjunctive 
treatment during therapeutic hypothermia (281). Brain MRI revealed substantially less 
moderate to severe brain injury, subcortical, and cerebellar injuries in the rEPO group as 
compared to the placebo group. Furthermore, after rEPO therapy motor outcomes at one 
year were improved (281). 
Melatonin is an endogenously synthesized neurotransmitter serotonin-derivative with anti-
apoptotic, anti-inflammatory, and effective antioxidant- and free-radical scavenger functions 
(220,282). It inhibits the production of proinflammatory cytokines and easily crosses 
physiologic barriers (220,282). Melatonin is a promising neuroprotective agent: In a recent 
small randomized study as an adjunctive therapy with hypothermia, the melatonin group 
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had a lower mortality rate, fewer seizures, less white matter injury on MRI, and improved 
intact survival at 6 months as compared with hypothermia only (294). 
Magnesium sulphate, which reduces glutamate-mediated excitotoxic damage after a 
hypoxic ischemic insult, is widely used and recommended for neuroprotection in preterm 
birth (282). In small randomized studies on term neonates with moderate to severe asphyxia 
or encephalopathy, postnatal magnesium sulphate treatment has significantly improved 
short-term neonatal outcomes (295,296). In magnesium-treated groups, rates of clinical 
neurologic and EEG aberrations, abnormalities in computerized tomography and MRI, and 
parenteral feeding were significantly lower. Long-term effects on neurodevelopment and the 
safety of usage remain to be confirmed before adoption of magnesium therapy to wider use 
(282). 
Stem cells derived from umbilical cord blood may be beneficial in HIE cases for 
neuroprotection (220,241). Endothelial progenitor cells which maintain and regulate 
vascular integrity and responses and multipotent mesenchymal stem cells enhancing tissue 
repair are especially promising possibilities (220). In animal studies on neonatal hypoxia-
ischemia, stem cells have reduced white matter injury and motor impairments (297).   
Allopurinol—a xanthine oxidase inhibitor—is a potential treatment in HIE, acting against 
oxidant injury caused by free radicals and superoxides (282). A small randomized follow-up 
study on neonatal allopurinol treatment demonstrated significantly less severe adverse 
neurodevelopmental outcomes among the neonates in the allopurinol-treated group with 
moderate HIE than suffered by control neonates (298). Ongoing studies are evaluating 
allopurinol as an adjunctive therapy with hypothermia (ALBINO Trial). Furthermore, some 
evidence exists on the neuroprotective effectiveness of antenatal allopurinol treatment. In 
a study on allopurinol treatment for fetal hypoxia, lower cord blood levels of protein S100B, 
a brain injury biomarker, occurred in neonates treated with allopurinol than in neonates with 
no maternal medication (299). 
Xenon—a noble gas used as inhalational anesthetic in adults—has displayed its 
neuroprotective ability in animal models (14). It inhibits N-methyl-D-aspartate (NMDA) 
glutamate receptors, thus reducing excessive glutamate concentrations and subsequent 
seizures after hypoxic ischemic injury (14,220). In a recent small randomized study on Xenon 
as an adjunct therapy with hypothermia, but initiated within 12 hours after birth, no 
difference between the xenon-treated group and control group appeared as measured by 
advanced MRI imaging techniques on neuronal tissue metabolism and integrity (300). Trials 
with different timeframe are ongoing (CoolXenon3 Trial). 
Additional therapeutic agents being studied as adjunctive therapies with hypothermia 
include the anticonvulsants topiramate and levetiracetam, N-acetylcysteine—owing to its 
antioxidant and anti-inflammatory properties, and monosialoganglioside to support cell-
membrane integrity (14,220,282). 
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SELECTED BIOMARKERS OF ASPHYXIA IN PERINATAL MEDICINE 
Rationale for searching biomarkers 
In certain obstetric circumstances, accurate timing and prediction of outcome of the delivery 
is challenging despite advanced monitoring methods (202,204,210,301). In diabetic 
pregnancies, for instance, normal CTG tracings, BPP scoring, and Doppler flow 
measurements are not always sufficient to assure fetal well-being (55). In IUGR pregnancies, 
Doppler flow parameters can progress in an unexpected manner (107,108); in post-term 
pregnancies, the value of various surveillance methods in preventing adverse outcome is not 
evident (109). Abnormal findings may appear as late manifestations of fetal distress and even 
by standardized surveillance methods, among risk-pregnancies unexpected fetal deaths 
occur (54,302). Thus, additional information on fetal wellbeing is desirable. Several new fetal 
biomarkers can detect fetal intrauterine hypoxia and to guide management of risk-
pregnancies. 
Currently, the only gold standard treatment for moderate and severe HIE is therapeutic 
hypothermia (20,241). The challenge is the narrow time-window in selecting patients and 
initiating treatment. Evaluation of an asphyxiated neonate and diagnosis of HIE utilizes 
clinical and biochemical signs, radiologic imaging, and electrophysiological monitoring (20). 
Such methods have certain limitations. MRI biomarkers appear after some delay following 
the insult (303), and the sensitivity and specificity as predictive markers in HIE of arterial cord 
blood pH values and Apgar scores are low (11). 
Up to 20% of newborns with an initial estimation of mild HIE later develop abnormal short-
term outcomes related to encephalopathy, and 40% have a Bayley score ≤ -1 SD—for either 
cognition, or motor, or language skills—at age 19 months (14,18). Infants with mild HIE have 
shown adverse cognitive and neuromotor outcomes at 5 years (14). Furthermore, among 
preterm neonates, more accurate prognostic markers are urgently needed. Correlations of 
diagnoses with defined status at initial discharge from hospital with severe 
neurodevelopmental outcome are poor. Of neonates classified initially as healthy, adverse 
neurologic outcomes such as CP or intellectual disability can appear in up to 20%  by age of 
two years (235). Thus, biomarkers could serve as adjunctive methods in screening neonates 
with subclinical or progressive lesions at early stages, and in monitoring  progression of the 
injury and effectiveness of treatments (19,20).  
Erythropoietin (EPO) 
EPO—a pleiotropic glycoprotein hormone—is the main regulator of erythropoiesis in adults, 
newborns, and fetuses (42). The primary stimulus for EPO production is hypoxia, with its the 
production rate related to the blood partial oxygen pressure (pO2) (304). Both EPO- and EPO-
receptor synthesis increase in response to proinflammatory cytokines and reactive oxygen 
species, as well (305). Hypoxia-inducible transcription factors (HIF-1, HIF-2) and hepatic 
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nuclear factor-4 (HNF-4) modulate EPO synthesis in oxygen-sensitive fibroblasts (286,306). 
Acute hypoxia in adult human leads to activation of EPO synthesis within 90 minutes (304). 
In animal studies, plasma concentrations of EPO begin to increase two to three hours after 
hypoxia (307). 
During the first and second trimesters, fetal EPO is produced in the yolk sac and liver. During 
the third trimester, the synthesis shifts gradually to peritubular fibroblasts in the kidneys 
(308). In addition to the kidneys, some synthesis of EPO and its receptors occurs in other 
tissues such as the lungs, spleen, blood capillaries, brain, uterus, and Leydig cells (305,308). 
It has been hypothesized that, during severe fetal hypoxia, EPO is produced also in the 
placenta, as in ovine studies (309). EPO and its receptors occur in human fetal membranes 
(310,311), and placental EPO gene expression is increased in fetal growth restriction (312). 
Furthermore, differences between umbilical venous and arterial EPO concentrations may 
indicate placental EPO synthesis (313).  
Functions of EPO. EPO-receptor activation leads to signal transmission cascades affecting 
various cellular functions such as apoptosis, proliferation, and differentiation (305). Within 
the bone marrow, EPO prevents apoptosis of erythroid progenitor cells, consequently 
resulting in erythrocyte synthesis (286). In addition to regulating red cell production, EPO 
plays a significant role in tissue-damage response (284). Tissue-protective effects of EPO 
arise in the central nervous system, peripheral nerves, heart, and retina (314-317). These 
two differing actions are mediated by different receptor isoforms each with a different 
affinity to EPO (318). Low concentrations of EPO are sufficient to cause increasing 
erythropoiesis in anemia; however, non-hematological actions require higher concentrations 
(318,319). EPO has short- and long-term tissue effects. Those in the short term include anti-
apoptotic, anti-inflammatory, and antioxidant properties, as well as bleeding-limiting actions 
which locally reduce blood flow and contribute to thrombus formation (284,305,320). Long-
term effects comprise erythropoietic, angiogenesis promoting, and neurotrophic actions 
(284,287,305,318,321). 
EPO in pregnancy and delivery. In the course of normal pregnancy, maternal EPO 
concentrations rise two- to four-fold; the timing and magnitude of changes are highly 
variable (322). Normal physical activity and exercise during pregnancy shows no effect on 
fetal EPO concentrations (323). Maternal anemia, however, raises fetal EPO, possibly 
reflecting fetoplacental hypoxemia (324). In complicated pregnancies such as ones with pre-
eclampsia, placental hypoxia may induce local EPO production, leading to increased 
maternal EPO concentrations (325). Maternal EPO can participate in humoral regulation of 
fetoplacental circulation by suppressing vasoconstrictive factors and may consequently 
provide a defensive mechanism to improve oxygenation of hypoxic fetus (326). 
Since EPO does not cross the placenta, EPO in the fetal circulation is of fetal origin (327,328). 
The half-life of fetal EPO is unknown, but in newborns it is 2 to 4 hours (25,329). In the 
majority of studies of normal pregnancies, EPO plasma levels remains stable after the second 
trimester (246,330,331). Some studies on healthy and complicated pregnancies have, 
however, found an increasing trend in EPO levels towards term, and found a correlation of 
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EPO plasma levels with gestational age (332-334). In pregnancies beyond 40 weeks, cord 
plasma EPO levels seem to increase progressively, most probably reflecting weakening 
placental function (335,336). 
EPO is transferred to amniotic fluid via some unknown mechanism, and its secretion into 
urine is considered an insufficient mechanism to explain its highly increased levels in hypoxia 
(25). Possible sources of EPO in amniotic fluid are the fetal membranes and the placenta 
(310-312). EPO concentrations in fetal plasma are higher than in amniotic fluid, but the 
concentrations correlate well in uncomplicated as well as in complicated pregnancies 
(246,337,338). Increased EPO production can be measured in amniotic fluid, but in hypoxia, 
am-EPO increases more slowly than fetal plasma EPO does, probably due to a delay in 
transfer (25). A moderate increase in am-EPO level may thus implicate early fetal hypoxia 
(25). In animal studies, EPO levels in amniotic fluid start to rise 6 hours later than the fetal 
plasma levels, approximately 9 hours after the beginning of hypoxia (307). 
Uterine contractions during normal vaginal delivery raise fetal EPO concentrations, and after 
uncomplicated vaginal birth, EPO concentrations in umbilical cord serum are higher than 
after planned cesarean sections (339). EPO levels in fetal plasma start to rise 6 hours after 
rupture of the membranes (323). These phenomena are most probably related to normal 
physiological processes and adaptation mechanisms at birth.  
Signs of fetal distress and EPO. In fetal hypoxia, EPO levels rise. Amniotic fluid EPO (am-EPO) 
is considered a biomarker of chronic hypoxia (25). In cord plasma, however, high EPO values 
may indicate acute hypoxia, as well (340). Elevated EPO levels have been detectable in cord 
plasma and amniotic fluid in various complicated pregnancies (25). It is assumed that in 
pathologic pregnancies when hypoxia has induced EPO synthesis, its secretion accelerates, 
and EPO levels increase exponentially (338,341,342). Such an increase occurs irrespective of 
the cause of fetal hypoxia (25). 
In several studies, cord plasma and am-EPO levels correlated inversely with umbilical artery 
pH, BE, and pO2, and directly with lactate and pCO2 values (246,337,342-344). Neonates 
with elevated EPO concentrations in amniotic fluid have decreased umbilical artery pH, BE, 
and pO2 at birth (338,342). Among risk-pregnancies, neonates with low Apgar score < 7 at 
one and five minutes have higher am-EPO concentrations than do vigorous newborns 
(338,345). Additionally, elevated am-EPO concentrations are associated with increased risk 
for neonatal intensive care admission (338,342).  
Various signs of fetal distress have shown an association with elevated EPO levels. Abnormal 
fetal heart-rate tracings during delivery are related to increased cord-plasma and amniotic-
fluid EPO concentrations (340,346,347). On the other hand, in high-risk pregnancies, am-EPO 
level can rise well before non-reassuring characteristics appear in heart tracings (338,342). 
Meconium staining of amniotic fluid is common, occurring at term deliveries in 7% - 22% 
(348,349). Its role as a hypoxia marker is controversial; nevertheless, it has been associated 
with elevated cord plasma EPO levels at birth (336,349,350). In addition, such elevated cord 
plasma EPO concentrations are associated with MAS (351). Among otherwise uncomplicated 
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deliveries, neonates with a nuchal cord had higher amniotic EPO concentrations without any 
effect on cord plasma EPO (352), probably reflecting transient hypoxic events before delivery 
resulting from cord entanglement. 
EPO in complicated pregnancies. Pregnancies with non-hypoxic complications such as 
cholestasis in pregnancy and prolonged rupture of the membranes are unrelated to 
increased fetal EPO concentrations (305,353). On the other hand, in complicated 
pregnancies involving various mechanisms leading to hypoxia, elevated EPO levels occur 
(313). Such an elevation in am-EPO can be considered as a sign of ominous fetal compromise 
(25). 
Elevated levels of EPO in cord plasma and amniotic fluid occur in relation to fetal growth 
restriction, especially in hypertensive pregnancies (338,347,354). Low birthweight < 2500 g 
is associated with elevated am-EPO levels (345). In addition, serum EPO levels may correlate 
with gestational-age-related fetal size in IUGR (355). One study evaluating am-EPO values in 
normally grown and SGA infants suggests that higher EPO values could differentiate growth-
restricted neonates from constitutionally small ones (356). In monochorionic twins showing 
discordant growth, the smaller fetus tends to have higher serum EPO values (357), but in 
some studies, this association has occurred only in relation to abnormal umbilical artery 
Doppler flow parameters (331). One study on IUGR pregnancies and Doppler flow 
parameters demonstrated increasing cord serum EPO concentrations in parallel with 
advancing fetal cardiovascular distress and deteriorating Doppler flow parameters (358). 
In cases of stillbirth, what may prove useful in investigating the cause of fetal death is am-
EPO evaluation. For days after fetal demise, EPO levels in amniotic fluid remain stable, with 
elevated levels detectable in deaths from chronic hypoxic events (359). A recent study 
demonstrated that most of its stillbirths, up to 88%, among structurally normal fetuses, 
involved placental dysfunction and hypoxia-based mechanisms of death. Am-EPO levels 
were significantly higher in stillbirths than in control pregnancies, especially in cases with risk 
factors for adverse pregnancy outcome, such as maternal hypertension or diabetes (69). 
Hypoxic complications and stillbirths occur relatively often in diabetic pregnancies 
(342,360). Both hyperinsulinemia and hyperglycemia may lead to fetal hypoxemia. In type-
1 diabetes, maternal glycated hemoglobin (HbA1c) levels reflecting long-term glucose 
balance may be directly correlated with fetal plasma and am-EPO levels (25,361). 
Maternal obesity is becoming a more common obstetric challenge, also being a signiﬁcant 
risk factor for intrauterine fetal death. In a recent retrospective cohort study, obesity was 
associated among term pregnancies with approximately 25% of stillbirths, a risk related to 
obesity severity (362). One possible mechanism might be increasing fetal hypoxia related to 
increasing maternal body mass index (BMI). With regarding to such hypoxia, cord-blood EPO 
concentrations are correlated with maternal BMI (363,364), as well as with poor pregnancy 
outcomes (364). In addition, maternal obesity promotes production of reactive oxygen 
species and hampers fetal iron supply, factors modulating fetal EPO levels (363,365). 
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In chronic fetal anemia, EPO values remain relatively low, unless hypoxia acutely worsens 
(341). This may be explainable by effective cardiovascular adaptations during this slowly 
progressing condition, or by accelerated EPO metabolism in anemia (319,341).  
Maternal smoking is associated with elevated cord plasma EPO levels independent of fetal 
growth restriction (366,367). Furthermore, these EPO levels are correlated with number of 
cigarettes smoked (368). Maternal opioid- or other illicit-substance abuse, however, is not 
significantly associated with cord blood EPO levels or with other hypoxia biomarkers such as 
S100B (334). Maternal alcohol consumption during pregnancy is related to elevated fetal 
cord serum EPO levels, but any connection with hypoxia remains unclear (369).  
EPO and adverse outcomes. High am-EPO levels predict adverse neonatal outcomes such as 
increased risk for prolonged intensive care unit admission, cardiomyopathy, metabolic 
disturbances, NEC, and neurologic morbidity (338,342,345). Furthermore, among 
asphyxiated neonates, high cord blood EPO is related to neonatal death or abnormal 
neurologic outcomes such as CP or delayed mental development at age two (274,340). In 
preterm births, elevated umbilical cord plasma EPO predict grade 3 to 4 IVH, independent of 
gestational age (370). 
High endogenous serum EPO levels during the first days of life predict increased risk for 
respiratory morbidity and severe NEC in extremely preterm infants. These levels, however, 
are unrelated to signs of postnatal hypoxia (371). High blood EPO values among preterm 
newborns are also associated with higher concentrations of inflammation-related proteins 
(372). On the other hand, EPO has tissue-protective functions and has potential in neonatal 
neuroprotection (281,284,285,287). Therefore, effects of endogenous and exogenous EPO 
are somewhat controversial (371). The mechanisms of EPO action are complex, and 
relationship of EPO with perinatal outcomes, especially with long-term outcomes, is yet not 
fully elucidated. 
S100B 
S100B is a calcium-binding protein expressed mainly in the central nervous system in glial 
cells, Schwann cells, and neurons, but also in extra-neuronal tissues (19,43). Its level in 
biological fluids; cerebrospinal fluid, peripheral and cord plasma, serum, urine, saliva, and 
amniotic fluid, is regarded as a biomarker of brain distress and of cell injury in the nervous 
system (43,373,374). It is associated with variable conditions including traumatic brain injury, 
stroke, neurodegenerative, congenital, and psychiatric diseases, as well as with extra-cranial 
injuries, which reduces its specificity (43,44). 
The exact function of intracellular S100B is still unknown. It participates in multiple 
intracellular activities such as cell proliferation, survival, and differentiation, as well as in 
regulation of calcium homeostasis and enzyme activation (43). Initially, S100B was assumed 
to leak from damaged neuronal cells, but recent evidence on active secretion of the protein, 
especially in association with metabolic stress, has emerged (373,375). S100B released into 
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the extracellular space interacts with adjacent cells in a manner dependent on its 
concentration and on environmental features of the tissue (19,376). At physiological low 
concentrations, S100B has paracrine trophic effects such as enhancing neuronal survival and 
promoting neurite extension and muscle regeneration (377). At high concentrations in a 
neural-injury response, however, S100B may trigger pathological processes leading to toxic 
and proinflammatory effects (43). 
In perinatal medicine, S100B is detectable in fluid compartments such as in amniotic fluid, 
cord plasma and serum, cerebrospinal fluid, serum, urine, and saliva. S100B, a relatively 
small protein with a half-life of only one hour, is capable of passing the brain-blood barrier 
into the peripheral blood stream (19). In high-risk pregnancies, fetal S100B appears also in 
maternal bloodstream (378). To some extent, S100B protein may be of placental origin (379). 
Cord plasma S100B concentrations correlate with gestational age (380) and are related to 
mode of delivery, with higher values in vaginal births (381). 
High amniotic fluid S100B concentrations can predict intrauterine death (45). In pregnancies 
with chronic fetal hypoxia, amniotic fluid S100B and EPO concentrations are correlative 
(382). Elevated S100B concentrations in cord plasma are also related to acidemia and 
asphyxia at birth (46,47). In addition, in asphyxiated newborns, elevated umbilical cord 
serum S100B concentrations predict development of moderate to severe HIE, and 
concentrations correlate with risk for neurological damage and death until six years of age 
(47). Increased S100B values in serum may predict abnormal cerebral hemodynamics and 
hemorrhage at an early phase, before occurrence of any clinical or radiological signs (19). 
Among neonates with perinatal asphyxia and HIE, high levels of serum S100B predict 
neonatal death and development of CP (383). Serum and urine levels of S100B within one 
week after delivery correlate with grade of HIE, risk for white-matter lesions and long-term 
neurologic morbidity, and risk of death (373,383,384). After perinatal asphyxia, neonates 
with hypothermia treatment show serum S100B levels that are lower (385). In addition, 
serum S100B levels in hypothermia-treated HIE neonates are predictive of long-term 
neurodevelopmental outcome at 15 months and at age 2 (385,386). Saliva S100B 
measurement is a non-invasive and easily achievable method and proving sensitive and 
specific as a marker of abnormal outcome in asphyxiated neonates with HIE (19). 
S100B is an extensively studied biomarker with reference values available for various 
biological fluids (19). It can serve as a prognostic marker and serve in monitoring the 
progression of certain disorders, but further data on correlations with radiologic findings and 
long-term outcomes are necessary (19,43). 
Arginine-vasopressin and copeptin 
Arginine-vasopressin (AVP), also known as antidiuretic hormone (ADH), regulates 
homeostasis of the cardiovascular and renal systems and is an important physiological stress 
hormone (387). AVP is synthesized in the hypothalamus and released from the pituitary in 
response to various stimuli such as decreased arterial pressure, reduced cardiac output 
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volume, and hypoxia (387,388). AVP is involved in regulation of numerous crucial body 
functions such as activation of the HPA axis, water absorption and homeostasis, behavioral 
and cognitive functions in the central nervous system, and hemostatic activity of platelets 
and endothelium (53,389). Direct measurement of AVP is, however, challenging because of 
its short half-life, pulsatile secretion, and platelet binding (389). Copeptin, however, a stable 
part of the vasopressin precursor molecule, is produced in equimolar ratio with AVP (389). 
Copeptin can thus serve for indirect demonstration of AVP production. As a novel biomarker, 
copeptin may be useful in diagnosis and prognosis of various conditions such as myocardial 
infarction, stroke, traumatic brain injury, and seizures in adult emergency departments (48-
50,390,391). 
During normal birth, release of fetal stress hormones occurs, ones including catecholamines, 
cortisol, and vasopressin (52,53,226). This endocrine activation supports the newborn’s 
transition phase and enhances breathing, adaptation of its cardiovascular system, 
thermogenesis, and glucose and water homeostasis (53,392). After vaginal birth, AVP and 
copeptin concentrations in cord plasma are significantly higher than after planned cesarean 
section (53). Uterine contractions cause transient episodes of fetal hypoxemia without 
inevitably affecting heart rate patterns or reducing arterial pH (26,53). Acute arterial hypoxia 
strongly stimulates AVP and copeptin excretion (393), and these brief hypoxemic events 
during contractions are sufficient to trigger AVP- and copeptin release (26). One hypothesis 
is that this phenomenon prepares the fetus for transition by activating the fetal HPA axis 
before birth (26,53). 
During the perinatal period, variable stressors enhance AVP and copeptin release (53). As 
compared to concentrations in planned cesarean section, AVP and copeptin plasma 
concentrations exceed those following acute cesarean section. Correspondingly, after 
assisted vaginal birth, the concentrations are higher than after spontaneous vaginal birth 
(51,53,392,394). Chronic stress resulting from IUGR is related to elevated cord-plasma 
copeptin concentrations (394). High concentrations of copeptin occur also in association 
with chorioamnionitis, non-reassuring CTG tracings, and perinatal asphyxia, both in pre-term 
and in term deliveries (51,52,395). Cord plasma AVP is of fetal origin (396). Concentrations 
of AVP and copeptin correlate with other cord-blood stress markers like pH, BE, and lactate 
(51-53,395). The highest cord plasma and serum values for AVP and for copeptin occur in 
association with perinatal hypoxia-ischemia (26,52,274,397). 
Cord-serum copeptin concentrations of asphyxiated neonates are only two-fold higher than 
are those of vigorous healthy newborns (52). The effects of AVP may differ between tissue 
hypoxia and normoxia (53). In a recent study on asphyxiated neonates, serum copeptin levels 
in the early neonatal period were higher among neonates with poor outcome (273). In 
addition, pre-term infants developing IVH have significantly elevated cord plasma copeptin 
concentrations at birth (395). Copeptin correlates with neuronal-damage biomarkers such 
as NSE, and high serum concentrations occur in the early phase after delivery (273). Thus, 
copeptin appears to be a promising biomarker of long-term neurodevelopment (273). 
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Current feasibility of the biomarkers EPO, S100B, and copeptin 
Technologies for swift laboratory assessments of these biomarkers do exist. For copeptin, 
rapid point-of-care testing is newly available (398). However, round-the-clock availability of 
assessments means increased financial costs. Thus, their current availability is limited (Table 
1). 
Table 1.  Feasibility of the biomarkers EPO, S100B, and copeptin 
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AIMS OF THE STUDY 
The aims of this study were to evaluate the role of biomarkers in identifying fetuses at risk 
for hypoxia-caused complications and in predicting neonatal outcomes after birth asphyxia. 
Additionally, we aimed to evaluate the association of gestational age with incidence of 
perinatal asphyxia and long-term neurologic morbidity in term and post-term pregnancies. 
The specific aims were the following: 
I To evaluate the association of amniotic fluid EPO levels with neonatal outcomes in 
preterm pregnancies < 34 GW complicated by IUGR. 
 
II To investigate whether, among relatively low-risk pregnancies, amniotic fluid EPO 
levels prior to labor can identify the individual fetuses at risk for intrapartum distress.  
 
III To examine the value of cord-serum copeptin as a biomarker for birth asphyxia, as 
compared with the value of EPO and of S100B. 
 
IV To evaluate the association of gestational age at birth – early-term, full-term, or 
postterm – with asphyxia, neurologic morbidity, and perinatal mortality. 
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SUBJECTS AND METHODS 
STUDY POPULATIONS AND OUTCOME MEASURES IN BIOMARKER STUDIES (I-III) 
All biomarker studies were conducted at the University Hospital of Helsinki, Finland, 
Department of Obstetrics and Gynecology. Gestational ages were defined by fetal crown–
rump length measurement at the first trimester ultrasound screening. Birth weight z-score 
in all the studies we defined according to the Finnish population standardized for gestational 
age (399). Inclusion and exclusion criteria (I-III) appear in Table 2. 
Table 2. Inclusion (+) and exclusion (-) criteria in Studies I-III 
 
Study I 
The study population comprised 98 women with singleton pregnancies complicated by IUGR, 
in which am-EPO determinations were performed during pregnancy. The study design was a 
retrospective case series, one covering pregnancies with preterm deliveries between 24 and 
34 GW during the years 2004 to 2012. Here, IUGR was defined as estimated fetal weight ≤ -
2 SD of the mean of the Finnish standard population, corresponding to growth as ≤ 3th 
percentile (399). After the exclusion of the 32 women shown in Table 2, the final study group 
comprised 66 women with delivery by cesarean section. These pregnancies were divided into 
two groups according to pathologic am-EPO and normal/intermediate am-EPO levels for 
data analysis. The main outcome measure was the association of am-EPO level with short-
term and composite adverse neonatal outcomes. 
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Study II 
This prospective observational study comprised 121 women with induction of labor by 
amniotomy. Women with pregnancies beyond 37+0 GW we recruited between September 
2012 and December 2014. Indications for induction included prolonged pregnancy (beyond 
41+0 GW), fear of childbirth, maternal exhaustion, mild pregnancy-induced hypertension, 
complications in a previous pregnancy, high-pool rupture of membranes in the absence of 
delivery contractions, gestational diabetes (non-medicated), fetus large-for-gestational age 
in a non-diabetic mother, unstable presentation, polyhydramnios, or intrahepatic cholestasis 
of pregnancy. According to our study protocol, no women with severe complications 
potentially causing fetal hypoxia were recruited (Table 2). Two women were excluded due 
to neonatal conditions, one with VACTERL syndrome and the other with nonketotic 
hyperglycinemia. After further exclusion of the 26 pregnancies lacking umbilical serum EPO 
(us-EPO) measurements, the final study group comprised 93 pregnancies. These 26 excluded 
pregnancies did not differ from the study population’s in terms of am-EPO levels, cesarean 
section rate, umbilical artery pH or BE, or Apgar score < 7 at one or five minutes. For data 
analysis, the 78 vaginal deliveries were divided into two groups according to gestational age: 
term (37+0- 40+6 GW) and prolonged pregnancies (41+0 GW). The outcome measures were 
association of EPO levels with short-term neonatal and delivery outcomes—umbilical pH, BE, 
Apgar score and intrapartum fetal distress—and with gestational age at birth. 
Study III 
The study population comprised 151 singleton births at or beyond 37+0 GW. Women were 
recruited for this prospective observational study between May 2012 and April 2013. For 
patient recruitment, low one-minute Apgar score < 4 allowed the swift identification of 72 
neonates with suspected birth asphyxia. Additionally, controls recruited were 79 neonates 
with one-minute Apgar score ≥ 4. Nine complicated pregnancies were excluded (Table 2). 
Additionally, one neonate was excluded due to a chromosomal anomaly and one for 
mitochondrial disease. Thus, the final study group comprised 140 neonates. They were 
divided into asphyxia and control groups for data analysis. Birth asphyxia we defined as the 
neonate’s meeting two of these three criteria: umbilical artery pH < 7.1, umbilical artery BE 
≤ -12 mmol/L, and five-minute Apgar score < 7 (21,248). All deliveries were planned as 
vaginal. The main outcome measure was association of biomarker levels with birth asphyxia. 
STUDY POPULATION AND OUTCOME MEASURES IN THE STUDY ON BIRTH ASPHYXIA AND 
LONG-TERM NEUROLOGIC MORBIDITY (IV) 
The population of this cohort study comprised 1 138 109 women with singleton term- and 
postterm deliveries and their infants born between 1989 and 2008. During the study period, 
gestational age was determined either by mother’s last menstrual period, or by first-
trimester ultrasonography. Deliveries of unknown gestational age numbered 7 230 (0.6%). 
Such deliveries were excluded from our study. In addition, we excluded stillbirths from all 
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analyses, except from perinatal mortality analysis. Live births included thus numbered 1 129 
481. Here, deliveries were divided into the following categories: early-term (37+0– 38+6 GW), 
full-term (39+0– 41+6 GW), and postterm (≥ 42+0 GW). Five-year periods included 1989–1993, 
1994–1998, 1999–2003, and 2004–2008. Perinatal deaths comprised both stillbirths and 
early neonatal deaths during the first seven days of life. Newborns with major congenital 
anomalies were excluded from mortality analyses. The main neonatal outcomes were 
associations of gestational age with birth asphyxia, perinatal mortality, and with long-term 
neurologic morbidity at age four years – including CP, epilepsy, intellectual disability, and 
sensorineural defects. 
CLINICAL DATA SOURCES 
In the biomarker studies (I-III), hospital charts provided the data on maternal and delivery 
characteristics including BMI in early pregnancy, in vitro fertilization, parity, gestational 
diabetes, smoking, chronic hypertension, medications used before and during the 
pregnancy, ultrasonography data recordings, gestation at delivery, and the primary 
indications for cesarean sections. Hospital charts provided the data on neonatal outcomes, 
such as one- and five-minute Apgar score, umbilical artery pH and BE, birthweight, and 
neonatal diagnoses and complications, as well. 
The Finnish Medical Birth Register (MBR) maintained by the National Institute for Health and 
Welfare (THL), provided data for our cohort study (IV). The MBR gathers baseline data 
concerning pregnancies, deliveries, and the newborn’s outcome during the first days of life 
on all live births and stillbirths beyond 22+0 GW and/or with birthweight ≥ 500g. Data 
collected for analyses covered the following variables: in vitro fertilization, smoking, parity, 
maternal age (<20, 20–34, and ≥35 years), delivery induction, mode of delivery, gestational 
age at birth, gender, birth weight < 2 500 g or ≥ 4 000 g, gestational age adjusted birth weight, 
SGA (< -2 SD) and large for gestational age (> +2 SD), diagnosis of MAS, low umbilical artery 
pH (< 7.00 and 7.00 – 7.10), and Apgar score < 4 at one and five minutes. Data on one-minute 
Apgar score were available for all newborns during the whole study period, whereas data on 
five-minute Apgar score were reported in the MBR since 2004, comprising 230 408 births 
(83.8%). Data on umbilical artery pH were included in the MBR in 1990 and were available 
for 519 210 births (45.9%). These data are collected at the time of birth from the mother’s 
prenatal charts. To complete the MBR data, basic information on the missing newborns 
(0.1%) are obtained from the Central Population Register and the Cause of Death Register. 
Data on diagnoses related to pregnancies and deliveries, plus children’s long-term neurologic 
diagnoses at age of four years, came from the Hospital Discharge Register (HDR) maintained 
by THL, containing nationwide linkable data on all inpatient hospital discharges. This register 
includes all inpatient and outpatient visits registered as due to CP, epilepsy, intellectual 
disability, and sensorineural defects (involving visual impairment and deafness) in public 
hospitals. Only occasionally are children treated in private hospitals and children who 
emigrated before established diagnoses missing from the HDR. A neurologic disorder at four 
years was recorded in the study if the child was detected in the HDR with ICD-9 (1989–1995) 
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or ICD-10 (1996–2008) codes for neurologic diagnoses (Figure 4). THL retains information on 
major congenital anomalies in the Register on Congenital Malformations. All the data 
linkages were performed by use of unique personal identity codes anonymized by relevant 
authorities. CP is typically evident within the first two years of life, and practically always by 
the age of three to four years (400). The Finnish public health care system invites all children 
to undergo annual physical examinations; thus, all neurologic diagnoses are consistently 
recognized by the age of four. Furthermore, multidisciplinary evaluations in secondary or 
tertiary pediatric neurology units are requirements for diagnosis of CP, epilepsy, intellectual 
disability, or sensorineural defects. These diagnoses are based on medical history, 
ultrasonography, and on MRI data, as required. 
 
Figure 4. Diagnosis codes for major neurological impairments from the international 
classification of diseases (ICD) 9 (years 1989- 1996) and ICD 10 (years 1997-2008).  
Seikku et al. 2016 (Study IV), modified with permission by American Academy of 
Pediatrics 
DEFINITIONS 
In all the studies, we defined obesity as BMI > 30 kg/m2. The diagnosis of gestational diabetes 
was based on the oral glucose tolerance test plasma glucose levels with values of ≥ 5.3 
mmol/L (fasting), ≥ 10.0 mmol/L (1 h) or ≥ 8.6 mmol/l (2 h) according to the American 
Diabetes Association (401). The American College of Obstetricians and Gynecologists (ACOG) 
has defined chronic hypertension in pregnancy as blood pressure ≥ 140/90 mmHg before 20 
weeks of gestation (402). Gestational hypertension was defined as a blood pressure level of 
≥ 140/90 mmHg in a previously normotensive woman after 20 weeks of gestation, without 
proteinuria (402). Pre-eclampsia was defined as a blood pressure level of ≥ 140/90 mmHg 
after 20 weeks of gestation with proteinuria more than 0.3 g per day, or with severe 
symptoms in a woman with previously normal blood pressure (402). MAS was defined (403) 
as the presence of meconium in both amniotic fluid and neonatal trachea, massive bilateral 
patchy infiltrates of the lung in thoracic radiograph, and profuse pleural fluid effusions. NEC 
was defined according to Bell’s staging system (404). Neonates fulfilling radiological and 
clinical criteria of stages II and III—“definite” and operatively treated stages—were included. 
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Ultrasound examinations and Doppler flow characteristics of the umbilical artery were 
carried out by perinatologists. Findings of absent or reverse end-diastolic flow were recorded 
if noted constantly. Oligohydramnios was defined as an amniotic fluid index less than four. 
Non-reassuring fetal heart rate was defined as the presence of decelerations or of a 
prolonged decrease in short- and long-time variability. Abnormal biophysical profile was 
defined as decreased or absent fetal movements and tone in ultrasound examination for 30 
minutes, oligohydramnios, or non-reassuring fetal heart rate patterns. 
Analysis of total perinatal mortality and early neonatal death was related to total number of 
births in the same gestational week. Data on stillbirths extracted from the MBR by use of the 
ICD codes were correlated with the numbers of ongoing pregnancies in the beginning of the 
gestational week. 
In Study I, composite adverse neonatal outcome was defined as the occurrence of at least 
one of the following diagnoses: necrotizing enterocolitis (NEC), grade III–IV intraventricular 
hemorrhage (IVH), periventricular leukomalacia (PVL), or cerebral infarction. Study II defined 
composite adverse outcomes if at least one of the following criteria applied: umbilical artery 
pH less than 7.15, umbilical artery BE less than -12 meq/L, one or five-minute Apgar less than 
7, or emergency cesarean section for fetal distress (203). 
SAMPLES AND ASSAYS 
Amniotic fluid samples 
Amniotic fluid samples for EPO measurements came either from amniocentesis (I), at 
delivery by cesarean section (I), or vaginally at induction of labor by amniotomy (II). 
Perinatologists performed the amniocentesis under ultrasound guidance by an aseptic 
technique within 7 days before delivery. In cesarean section, the amniotic fluid samples were 
obtained after hysterotomy and before amniotomy by syringe. Collection of vaginal samples 
was at the time of amniotomy from the vaginal pool with a plastic cup and syringe. The EPO-
level analysis occurred only after birth, and they had no influence on clinical management. 
We compared am-EPO levels in vaginally collected samples with those obtained by 
amniocentesis in five patients who had an amniocentesis for fetal lung maturation 
assessment followed by induction of labor by amniotomy. The correlation between these 
sampling methods was strong (r = 0.9, p = 0.037). 
Umbilical cord samples 
Collection of umbilical cord blood samples was immediately after birth (I, II, III). Umbilical 
artery pH, BE, pO2, and pCO2 measurement occurred routinely with the Radiometer ABL800 
Flex blood gas analyzer (Radiometer, Copenhagen, Denmark). 
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Biomarker assays 
EPO levels in amniotic fluid (I, II) and umbilical cord serum at birth (II, III) we measured with 
a solid-phase immunochemiluminometric assay (Immulite 2000XPI, Siemens Healthcare 
Diagnostics, Tarrytown, NY, USA). The intra-assay coefficient of variation (CV) of the assay 
was 3.6% to 6.8%, and the total CV 6.4% to 10.3% for the concentration range 4–615 IU/L. 
The detection limit was 1.0 IU/L, with functional sensitivity (CV of 20%) of 1.5 IU/L. The 
Immulite standard of measuring EPO in amniotic fluid changed during Study I. EPO levels 
analyzed by the old standard were correlated with the new Immulite 2000 EPO standard by 
use of a regression equation. We classified am-EPO levels into three categories 
(normal/intermediate/abnormal) as previously described (338). The normal level of EPO in 
umbilical cord serum we defined as < 40 IU/L (25). 
We measured copeptin levels in umbilical serum with a sandwich enzyme-linked 
immunosorbent assay (ELISA). The inter-assay variability was 5.8%. Fifteen serum samples 
were analyzed with both the ELISA and the BRAHMS copeptin Kryptor assay used earlier 
(51,52). A highly significant correlation occurred (Pearson r = 0.9793, p < 0.0001), covering 
the full range of values obtained (6.0 to 4 637 pmol/L, median 381.2 pmol/L). Thus, copeptin 
concentrations obtained with the ELISA we converted to Kryptor concentrations to enable 
direct comparisons of our data with the earlier copeptin results. 
We measured serum S100B levels with an electro chemiluminometric immunoassay by 
Modular e170 analyzer (Roche Diagnostics). The detection range was 0.005 μg/L, and 
functional sensitivity < 0.02 μg/L. The intra-assay CV was < 2.1%, and the inter-assay variation 
6.4%. 
STATISTICAL ANALYSES 
Characteristics of the newborns and their mothers appear as means with standard deviations 
(SD) in normally distributed continuous variables, by medians with interquartile range in 
skewed distributed variables, and in categorial variables by number of values and 
percentages. We compared groups by using the Mann-Whitney U-test or the χ2 test, when 
appropriate. Comparisons of continuous variables in more than two groups were by the 
Kruskal-Wallis test. We calculated correlations by Spearman´s rank correlation coefficient 
test or Pearson’s test, as appropriate. Statistical outliers (p < 0.01) for copeptin and S100B (n 
= 1 for each) were excluded from the study population prior to performance of calculations. 
The receiver operating characteristics (ROC) curves were constructed and areas under the 
curves (AUC) determined to evaluate diagnostic accuracy of am-EPO in predicting adverse 
neonatal outcome (I) and accuracy of copeptin in diagnosing birth asphyxia (III). Risk factors 
for neonatal asphyxia and neurologic adverse outcome we evaluated by logistic regression 
analyses using multivariate models, described as odds ratios (ORs) with 95% confidence 
intervals (CIs). 
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Statistical analyses were with the Statistical Package for Social Sciences (SPSS, Chicago, IL, 
USA) versions 18.0 (I), 20.0 (IV), or 22.0 (II, III). Additionally, GraphPad Prism 6 (III) and SAS 
version 9.3 (SAS Institute, Inc, Cary, NC, USA) were utilized. All the tests were two-sided, with 
probability (p) values of < 0.05 considered statistically significant. 
ETHICS 
The local Ethics Committee of the Department of Obstetrics and Gynecology, Helsinki 
University Hospital, Finland (105/13/03/03/2012, 105/13/13/03/2012), approved the 
biomarker studies (I, II, and III). All participants provided informed written consent to 
participate in the study. THL, as the register keeper, provided the necessary authorization 
for Study IV, as required by national data protection legislation (THL/1200/5.05.00/2012).  
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RESULTS 
BIOMARKER STUDIES (I-III) 
Table 3 presents selected demographic and clinical characteristics of the populations in 
Studies I, II, and III. 
Table 3. Characteristics of the study populations 
 
Study I on 66 IUGR pregnancies compared 56 (84.8%) pregnancies with normal or 
intermediate am-EPO levels with 10 (15.2%) pregnancies with abnormal EPO levels. Among 
the whole population in this study, hypertensive disorders were excessive, with up to 31.8% 
of the women (n = 21) having chronic pre-pregnancy hypertension, and with 18.2% (n = 12) 
developing pregnancy-induced hypertension, and 40.9% (n = 27) with pre-eclampsia. Study 
II compared am-EPO and us-EPO levels in 30 (32.3%) term pregnancies to 63 (67.7%) 
prolonged pregnancies ≥ 41+0 GW. Study III comprised 140 term and postterm pregnancies, 
which were divided into two groups for data analysis: 27 (19.3%) neonates with birth 
asphyxia and 113 (80.7%) healthy controls. 
No statistically significant differences emerged in maternal or delivery characteristics 
between any of these study groups. Maternal BMI correlated with am-EPO (r = 0.323, p = 
0.008) in Study I. Other baseline characteristics of the study populations, including the 
hypertensive disorders in Study I, failed to correlate with biomarker levels. 
AMNIOTIC FLUID AND UMBILICAL SERUM EPO (AM-EPO AND US-EPO) (I-III) 
Am-EPO and us-EPO levels in Studies I, II, and III are shown in Table 4. In Study II, am-EPO 
levels in samples collected before delivery contractions correlated with us-EPO levels at birth 
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(r = 0.480, p < 0.000), and this correlation was sustained after vaginal delivery (n = 78, r = 
0.513, p < 0.000). 
Table 4. Amniotic fluid and umbilical serum levels (I-III) 
 
Correlation of EPO with gestational age (I-III) 
In Study I on preterm IUGR pregnancies, am-EPO did not correlate with gestational age (p = 
0.674). Among term and prolonged pregnancies (II), a correlation between am-EPO level and 
gestational age occurred (r = 0.261, p = 0.012) (Figure 5). Am-EPO levels were higher in 
prolonged pregnancies ≥ 41+0 GW (median 7.1 IU/L), than in term pregnancies (median 3.9 
IU/L) (p = 0.005). 
 
Figure 5. Amniotic fluid EPO levels related to gestational weeks. Seikku 2019 et al. (Study II), 
modified with permission by Elsevier 
In Study II, us-EPO levels in umbilical serum correlated with gestational age among the 78 
(83.9%) vaginal deliveries (r = 0.250, p = 0.027). The us-EPO levels did not differ between 
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prolonged and term pregnancies (p = 0.057) (Table 5). Correspondingly, in Study III, EPO 
levels in cord blood correlated with gestational age at birth (r = 0.451, p < 0.0001). 
Table 5. A comparison of term and prolonged pregnancies in the vaginal delivery group (n=78) (II) 
 
Am-EPO and fetal parameters (I) 
Absent end-diastolic flow in the umbilical artery did not associate with abnormal EPO in 
amniotic fluid (Table 6). However, along with further deterioration in umbilical artery flow—
in reversed end diastolic flow—an association with abnormal EPO arose (p = 0.042). 
Abnormal biophysical profile was associated with abnormal am-EPO (p < 0.001), whereas 
oligohydramnios was not. 
Table 6. Umbilical artery Doppler flow and biophysical profile characteristics according to 
am-EPO values. Seikku et al. 2015 (Study I), modified with permission by John Wiley 
and sons 
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EPO and neonatal outcomes (I-III) 
Study I. Growth restriction (≤ 2.0 SD) was observable in 62 (94%) of the neonates at birth, 
severe growth restriction (birthweight ≤ 3.0 SD) comprising 53% of the population (n = 35). 
Degree of growth restriction did not correlate with am-EPO levels (p = 0.852) (Table 7). 
Table 7. Selected neonatal characteristics and outcomes by amniotic fluid EPO levels. Seikku 
et al. 2015 (Study I), modified with permission by John Wiley and sons 
 
Among preterm IUGR pregnancies, an inverse correlation occurred between levels of am-
EPO and umbilical artery pH (p = 0.001, r = -0.433) and BE (p = 0.001, r = -0.418) (Figure 6). 
Furthermore, pH and BE at birth were lower among the neonates with abnormal am-EPO (p 
= 0.027 and p = 0.007). 
 
Figure 6. Correlation of amniotic fluid EPO with umbilical artery pH and base excess (log scale) 
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Composite adverse neonatal outcome, defined as intraventricular hemorrhage, 
periventricular leukomalacia, cerebral infarction, or NEC, was significantly more common 
among those neonates with abnormal am-EPO (p < 0.001). In predicting composite adverse 
neonatal outcome by the receiver operating characteristic (ROC) curve, the best cut-off value 
of am-EPO was 25.0 IU/L with sensitivity of 63.6% and specificity of 96.4%, and with AUC 
0.803 (95% CI 0.633 – 0.947, p = 0.002). Neither umbilical artery flow parameters nor 
gestational age at birth associated with composite adverse neonatal outcome. 
No stillbirths occurred in the study population. The overall mortality of the population at age 
6 months was 6.1%, with one perinatal death at ≤ 7 days and three infant deaths, all due to 
prematurity-related complications. Mortality was not higher in the group with abnormal am-
EPO levels (Table 7). 
Study II. In term- and prolonged low-risk pregnancies (II), abnormal am-EPO level occurred 
in only three (3.2%) (Table 4), with no correlation of am-EPO levels with umbilical artery pH 
or BE (r = 0.092, p = 0.381, and r = 0.051, p = 0.626, respectively). Neither was there a 
correlation of umbilical cord serum EPO level with umbilical artery pH nor BE (p = 0.897, p = 
0.390). 
Composite adverse outcomes—defined as umbilical artery pH ≤ 7.15, umbilical artery BE ≤ -
12 meq/L, one or five-minute Apgar < 7, and/or emergency cesarean section for fetal 
distress—occurred in 18 of the deliveries (19.4%). Am-EPO or us-EPO levels were no higher 
among those pregnancies ending in adverse outcomes, than among the uncomplicated 
deliveries (p = 0.903, and p = 0.059, respectively). Furthermore, no difference in adverse 
outcomes appeared between the term (10%) and prolonged pregnancies (28.2%) (p = 0.162). 
Vaginal delivery succeeded in 78 (83.9%) pregnancies. Indications for acute cesarean 
sections included three with fetal distress during delivery, seven with labor dystocia, four 
chorioamnionitis, and one fetal malpresentation. Am-EPO levels were comparable among 
women with vaginal delivery (median 6.0 IU/L, range 0.5–58.2 IU/L) and cesarean section 
(median 5.8 IU/L, range 1.6–89.8 IU/L) (p = 0.350). No difference emerged in cesarean 
section rates between the term and prolonged pregnancies (p = 0.232). 
Study III. In this study, the birth asphyxia group comprised neonates with two of these three 
criteria: umbilical artery pH < 7.10, umbilical artery BE ≤ -12 mmol/L, or a 5-min Apgar score 
< 7 (Table 8). 
Us-EPO-level values did not correlate with umbilical artery pH (r = -0.145, p = 0.144). 
However, correlations appeared between us-EPO levels and umbilical artery BE (r = -0.174, 
p = 0.04), and five-minute Apgar score (r = -0.291, p <0.001), but no difference in us-EPO 
between asphyxia and control groups (p = 0.683). 
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Table 8. Comparison of delivery and neonatal characteristics of the study populations (III). 
Summanen et al. 2017 (Study III), modified with permission by Karger 
 
Delivery characteristics and EPO 
In Study II, us-EPO levels among the vaginal deliveries (median 32.7 IU/L) and the acute 
cesarean sections (median 32.9 IU/L) were comparable (p = 0.222).  
Study III comprised 89 (63.6%) vaginal births and 51 (36.4%) acute cesarean sections. 
Vacuum extractions occurred in 37.1% of the 33 vaginal births, with no difference in delivery 
mode between asphyxia and control groups (Table 8). EPO levels were higher among 
neonates born by cesarean section than born vaginally—both spontaneously and by vacuum 
extractions (medians 116.0 IU/L, 38.3 IU/L, and 32.3 IU/L, respectively, p = 0.0002 and p = 
0.001), with no difference in EPO levels between spontaneous vaginal deliveries and vacuum 
extractions occurred (p = 0.983). 
Umbilical cord serum EPO levels did not correlate with total duration of labor or duration of 
the second stage of labor in either of the studies II (p = 0.287 and p = 0.783) or III (p = 0.276 
and p = 0.763). 
UMBILICAL SERUM S100B (III) 
The median umbilical serum S100B level in the study population was 0.31 ug/L (range 0.04 – 
4.03 ug/L). Umbilical serum S100B levels did not correlate with gestational age (r = -0.002, p 
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= 0.984). Among male neonates, S100B levels were higher than among those who were 
female (medians 0.33 ug/L and 0.28 ug/L, p=0.038). 
Umbilical serum S100B level did not correlate with umbilical artery pH (r = -0.125, p = 0.144). 
Nevertheless, a correlation did appear between S100B level and umbilical artery BE (r = -
0.218, p=0.01). Umbilical serum S100B correlated with Apgar score at 5 and 10 minutes (r = 
-0.204, p = 0.016 and r = -0.205, p = 0.016), but no difference appeared in S100B levels 
between the birth asphyxia group and unaffected controls (p = 0.712) (Table 8). 
We found no differences in S100B levels between spontaneous vaginal, vacuum-extraction, 
or cesarean-section deliveries (S100B medians 0.30 ug/L, 0.33 ug/L, and 0.33 ug/L, 
respectively; p = 0.476). S100B was not correlated with total duration of delivery nor with 
duration of second stage of delivery (r = 0.125, p = 0.244, and r = 0.104, p = 0.333). 
UMBILICAL SERUM COPEPTIN (III) 
Median umbilical serum copeptin level was 1217.5 pmol/L (range 0.0 - 7107.6 pmol/L), with 
no correlation of copeptin levels with gestational age at birth, or with the sex of the neonate, 
occurred (r = 0.064, p = 0.452, and p = 0.337). Copeptin levels correlated significantly with 
birth weight (r = -0.171, p = 0.044). 
Umbilical serum copeptin levels correlated with arterial pH (r = -0.622, p < 0.001) and with 
umbilical artery BE (r= -0.37, p <0.001). Additionally, copeptin correlated with Apgar score at 
5 and 10 minutes (r= -0.230, p <0.001, and r = -0.168, p = 0.048). Copeptin levels were higher 
among those neonates with birth asphyxia than among the unaffected controls (medians 2 
279 and 974 pmol/L, p < 0.001). By receiver operating characteristic (ROC) curve, the best 
cut-off value of copeptin was 1 522 pmol/L in predicting asphyxia (sensitivity of 77% and a 
specificity of 70%), with the AUC of 0.76 (95% CI 0.69 - 0.86) (Figure 7). 
 
Figure 7. ROC curve for cord serum copeptin levels in relation to birth asphyxia. The dashed 
lines demonstrates the optimal discriminative cutoff of 1522 pmol/L, with sensitivity 
77% and specificity 70% 
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Copeptin levels and delivery characteristics 
Umbilical serum copeptin medians according to delivery mode were as follows: spontaneous 
vaginal birth 1052.7 pmol/L, vacuum-assisted birth 1611.7 pmol/L, and acute cesarean 
section 793.8 pmol/L (p=0.004). Copeptin levels were higher among neonates born vaginally 
than among those born by cesarean section (p = 0.020). A difference occurred especially 
between vacuum-assisted vaginal births and cesarean sections (p = 0.001), but also in 
vacuum-assisted births as compared with spontaneous vaginal births (p = 0.019). Among 
vaginally born neonates, copeptin levels increased as a function of total labor duration (r = 
0.327, p = 0.002), as well as of duration of the second stage of labor (r = 0.279, p = 0.009).  
COMPARISON OF UMBILICAL SERUM BIOMARKERS COPEPTIN, EPO, AND S100B (III) 
Copeptin was the only biomarker correlating with umbilical artery pH (Table 9). The 
correlation of umbilical artery BE with copeptin was stronger than was its correlation with 
EPO or S100B. Additionally, only their copeptin levels were significantly higher among 
neonates with birth asphyxia. Furthermore, copeptin levels increased as a function of labor 
duration among vaginally born neonates. Copeptin levels correlated with S100B levels (r = 
0.295, p < 0.001). Us-EPO correlated with neither copeptin nor S100B (r = 0.106, p = 0.218 
and r = 0.24, p = 0.780, respectively). 
Table 9. Correlations of the biomarkers with neonatal variables 
 
ASPHYXIA AND NEUROLOGIC MORBIDITY (IV) 
Table 10 demonstrates maternal and delivery characteristics of this study covering 1 129 481 
live births, including 214 465 (19.0%) early-term and 55 189 (4.9%) postterm births.  
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Table 10. Maternal and delivery characteristics of the study population. Seikku et al. 2016 (IV), 
modified with permission by American Academy of Pediatrics 
 
Delivery induction was more common among both early-term (15.8%) and postterm births 
(45.0%) than among full-term births (12.6%) (OR 1.12, 95% CI 1.11–1.14, and OR 6.30, 95% 
CI 6.19–6.42, respectively). Additionally, the rate of emergency cesarean delivery was higher 
for early-term (10.2%) and postterm births (15.5%) than for full-term births (7.2%) (OR 1.40, 
95% CI 1.37–1.42, and OR 2.31, 95% CI 2.25–2.36, respectively). 
Table 11 includes the neonatal characteristics, and Figure 8 presents the incidences of low 
umbilical artery pH ≤ 7.10, and low Apgar scores at 1 and 5 minutes. 
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Table 11. Neonatal characteristics of the study population. Seikku et al. 2016 (IV), modified 
with permission by American Academy of Pediatrics 
 
 
 
Figure 8. Incidences of low umbilical artery pH and low Apgar score at 1 and 5 minutes 
according to gestational weeks. Seikku et al. 2016 (IV), modified with permission by 
American Academy of Pediatrics 
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Early-term birth and early morbidity 
Early-term birth was an independent risk factor for low Apgar score at 1 and 5 minutes, as 
analyzed by logistic regression (OR 1.03, 95% CI 1.03–1.04, and OR 1.24, 95% CI 1.04–1.49, 
respectively). In contrast, early-term birth was not associated with low umbilical artery pH 
≤7.10 (OR 0.83, 95% CI 0.79–0.87) or pH <7.00 (OR 1.06, 95% CI 0.96–1.18). 
Postterm birth and early morbidity 
By logistic regression analysis, postterm birth was an independent risk factor for low Apgar 
score at 1 and 5 minutes (OR 1.26, 95% CI 1.26–1.26, and OR 1.80, 95% CI 1.43–2.34, 
respectively). Furthermore, postterm birth was an independent risk factor for low umbilical 
artery pH ≤7.10 (OR 1.26, 95% CI 1.19–1.34) and pH <7.00 (OR 1.18, 95% CI 1.02–1.37]. MAS 
was more common in postterm than in full-term pregnancies (OR 3.20, 95% CI 3.20–4.16). 
The risk factors for long-term morbidity 
The results of our risk factor analysis for neurologic morbidity are in Table 12. Induction of 
delivery was not associated with increased risk for CP, but an association with risk for 
epilepsy emerged. Emergency cesarean section was associated with neurologic morbidity: 
CP, epilepsy, intellectual disability, and sensorineural defects.  
Low Apgar score at 1 and 5 minutes were independent risk factors for these sequelae, as was 
low umbilical artery pH—especially pH < 7.00, but even at pH values from 7.00 to 7.10 (Table 
12). 
 
 
 
 
 
 
Table 12. Risk factor analysis for cerebral palsy, epilepsy, mental retardation, and sensory 
neural defects. Seikku et al. 2016 (Study IV), modified with permission by American 
Academy of Pediatrics 
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In logistic regression analysis, early-term birth was another independent risk factor for CP, 
epilepsy, intellectual disability, and sensorineural defects (Table 12). Among children born 
early term, 14.0% of newborns with pH < 7.10 had one-minute Apgar < 4, and 37.7% of 
newborns with pH < 7.00 had one-minute Apgar < 4. 
Postterm birth was an independent risk for intellectual disability. However, no associations 
with CP, epilepsy, or sensorineural defects appeared (Table 12). Among post-term births, 
8.8% newborns with pH < 7.10 had one-minute Apgar < 4, and 33.3% of newborns with pH < 
7.00 had one-minute Apgar < 4. MAS was associated with intellectual disability, but not with 
CP or epilepsy (Table 12). 
Data on long-term neurologic impairment rates according to gestational age are in Table 13. 
The incidence of CP decreased over the study period from 0.26% during the years 1989 to 
1993 to 0.15% during 2004 to 2008 (p < 0.001). During the same time periods, the incidences 
of epilepsy (from 0.19% to 0.48%), intellectual disability (from 0.16% to 0.25%), and 
sensorineural defects (from 0.09% to 1.04%) increased (p < 0.001 for all). No changes 
occurred in rates of early-term or postterm birth rates during the study period. 
Table 13. Neurological impairments at age 4. Seikku et al. 2016 (Study IV), modified with 
permission by American Academy of Pediatrics 
  
PERINATAL MORTALITY (IV) 
Total perinatal mortality of the study population, excluding neonates with major congenital 
anomalies, was 1.3 per 1000 births. Neonates born at early term had the highest incidence, 
with 2.5 deaths per 1000 births. Among full-term neonates, the incidence was 1.0 per 1000 
and postterm neonates 0.9 per 1000 births. The risk for early neonatal death within the first 
seven days was higher after early-term and postterm births, than after full-term births (Table 
14). Stillbirth risk, as related to ongoing pregnancies, was lower in both early-term and 
postterm births (Table 14). Total perinatal mortality rates decreased during the study period 
mostly due to a decreased stillbirth rate (p < 0.001). Early neonatal death rate, however, did 
not fall significantly (p = 0.071) (Figure 9). 
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Table 14. Risk for perinatal mortality in early- and postterm birth as compared to full term 
birtha. Seikku et al. 2016 (Study IV), modified with permission by American Academy 
of Pediatrics 
 
 
  
Figure 9. Perinatal mortality rates during years 1989 - 2008 (IV) 
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DISCUSSION 
BIOMARKER STUDIES (I-III) 
Alterations in biomarker levels during delivery are at least in part due to physiological fetal 
adaptations in the transition phase. “Ischemic preconditioning” refers to a phenomenon in 
which an ischemic insult below the damage-causing threshold activates endogenous 
protective mechanisms. Such priming may reduce the effect of subsequent, possibly more 
severe, insults (405). The extent of any advantage from these protective responses depends 
on circumstances. Some reactions, such as increased AVP secretion during birth, may be 
necessary and useful under normal conditions, but be harmful in association with asphyxia 
(53). Interpretation of the biomarker evaluations is thus complex. The same phenomenon 
may be related to the physiological decrease in umbilical artery pH during normal birth (406), 
a phenomenon possibly involved in triggering adaptation processes. 
AMNIOTIC FLUID AND UMBILICAL SERUM EPO (AM-EPO AND US-EPO) (I-III) 
EPO in amniotic fluid is a biomarker of chronic fetal asphyxia (25). Increased EPO levels in 
fetal plasma or in umbilical cord serum at birth may also reflect subacute hypoxia (340). 
Elevated EPO levels have been associated with decreased umbilical artery pH, BE, and Apgar 
score, as well as with increased risk for neonatal intensive care admission in various 
pathologic pregnancies (25,344,345). On the other hand, EPO has tissue- and 
neuroprotective features (281,284,313). Thus, increased EPO levels may reflect 
preconditioning and an effort toward tissue protection, even though endogenous EPO levels 
may not always prove sufficient (371). 
Am-EPO sampling methods 
Both methods of am-EPO sampling—amniocentesis and vaginal sample at amniotomy—have 
been used, sometimes as equivalent methods in the same study (340,345). The presence of 
blood in the amniotic fluid tends to elevate EPO values, whereas meconium has no influence 
on EPO levels (345). We compared amniotic fluid samples collected first by amniocentesis, 
followed by samples collected at amniotomy in the same patients, and found a substantial 
correlation between these methods. Amniocentesis is a relatively safe invasive method, with 
complications requiring immediate delivery occurring in only 0.7% (407). More common 
complications such as preterm rupture of the membranes and bleeding, occur in an 
estimated 3.6% (408). In our study, no complications due to amniocentesis occurred. 
However, the advantages of vaginally obtained—noninvasive sampling—needs further 
evaluation. 
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Am-EPO and maternal characteristics (I, II)  
Maternal obesity has been associated with increased risk for IUGR, especially when utilizing 
customized centiles for fetal-growth estimation (409). Additionally, perinatal mortality risk 
increases in correlation with maternal BMI (409). In Study I, we found a correlation of 
maternal BMI with am-EPO. This may reflect increased risk for hypoxia with higher BMI 
among IUGR pregnancies. However, among relatively low-risk pregnancies (II), no such 
association was evident. 
Earlier studies have demonstrated higher am-EPO levels in pregnancies with hypertensive 
complications than in uncomplicated pregnancies (338). We found no association of am-EPO 
levels with hypertensive disorders (I), which may be explained by our study population’s 
comprising only pregnancies complicated by fetal growth restriction. 
Correlation of EPO with gestational age (I-III) 
In uncomplicated pregnancies—during normoxia—fetal EPO levels remain relatively stable 
throughout the second and third trimesters (330). However, studies have demonstrated 
increasing EPO levels beyond 41 GW (335). Consistent with this, among the preterm 
pregnancies (I), am-EPO did not correlate with gestational age, whereas among the term and 
prolonged pregnancies (II) a correlation of am-EPO level with gestational age appeared, with 
significantly higher EPO levels among prolonged pregnancies. Furthermore, EPO levels in the 
umbilical serum in the term and prolonged pregnancies (II, III) correlated with gestational 
age. In us-EPO, the difference between term and prolonged pregnancies was non-significant 
(II), which is understandable, as the risk for adverse perinatal outcomes in term pregnancies 
increases gradually after 40 pregnancy weeks (191). Increasing levels of EPO along with 
advancing gestation are in line with the hypothesis that gradual weakening of placental 
function and incipient relative hypoxia explains the increased risk for fetal compromise in 
prolonged pregnancies. 
Am-EPO and parameters of fetal wellbeing (I) 
Widely established in management of pregnancies with fetal growth restriction is Doppler 
flow assessment. Abnormalities in umbilical-artery flow parameters such as absent or 
reversed end-diastolic flow, are associated with intrauterine hypoxia and increased risk of 
perinatal mortality (155,156). Our study is, to the best of our knowledge, the first to report 
am-EPO in relation to umbilical artery Doppler flow changes. We found an association 
between reversed—but not absent—end-diastolic flow in the umbilical artery and abnormal 
am-EPO levels. This finding is consistent with the increasing risk for fetal hypoxia along with 
deteriorating umbilical artery flow, as are earlier findings on IUGR pregnancies 
demonstrating a positive correlation between umbilical artery pulsatility (PI) index and cord 
serum EPO at birth (358). In our study, an association of umbilical artery Doppler flow 
changes with adverse neonatal outcome was, however, lacking. This is in line with some 
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earlier findings of increased morbidity in IUGR pregnancies even in the absence of umbilical 
artery flow abnormalities (301) and suggests that prediction of chronic fetal hypoxia and 
adverse neonatal outcomes cannot be based on umbilical Doppler flow parameters alone. 
Biophysical profile assessments serve in detecting hypoxia-related changes in fetal status 
(151). Abnormal biophysical-profile findings are associated with fetal acidosis, stillbirth, and 
CP (82). We demonstrated a strong association of abnormal biophysical profile with 
abnormal am-EPO levels. Biophysical profile scoring is, however, a subjective method, and 
its clinical utility is limited. Furthermore, an abnormal biophysical profile may appear at late 
stages of fetal hypoxia and indicate irreversible fetal compromise (60). Placental insufficiency 
generally leads to decreased amniotic volume, which may occur at earlier stages than do the 
other changes in biophysical profile (92). In our study, oligohydramnios was not significantly 
related to abnormal EPO levels, indicating that subtle weakening of placental function does 
not cause significant changes in EPO levels. When the indication is for immediate delivery, 
EPO assessment by amniocentesis is no longer useful. 
Correlation of am-EPO with us-EPO (II) 
A correlation exists between EPO levels in amniotic fluid and in fetal plasma, as well as with 
umbilical cord serum after delivery by planned cesarean section (25,338). EPO levels in fetal 
plasma rise in response to hypoxic events more quickly than do the levels in amniotic fluid 
(25). Consequently, umbilical cord serum EPO levels may be elevated in subacute hypoxia 
during delivery. We confirmed that EPO levels in amniotic fluid before the delivery 
contractions remain correlated with us-EPO levels at birth, even after the stress caused by 
vaginal delivery.  
Associations of EPO with umbilical artery pH and BE (I-III) 
Increased levels of EPO in amniotic fluid and fetal plasma indicate chronic hypoxia and can 
be detectable in various pathological pregnancies such as Rhesus alloimmunization, fetal 
growth restriction, pre-eclampsia, and maternal type 1 diabetes (25). High fetal and am-EPO 
levels have been associated with acute adverse neonatal outcomes such as decreased 
umbilical cord pH, BE, and pO2, and increased risk for intensive-care-unit admissions (25). 
Moreover, increased umbilical plasma EPO levels at birth are associated with increased 
mortality rates and risk for neurodevelopmental abnormalities at age two (274). 
In our study on IUGR pregnancies (I), am-EPO showed an inverse correlation with umbilical 
artery pH and BE, with abnormal am-EPO levels being associated with significantly lower 
umbilical artery pH and BE values, consistent with findings in several studies (342,344). 
However, in a study by Girsen et al. on IUGR pregnancies, only cord blood BE correlated with 
EPO levels at birth (358). In their study, one-third of the population had a vaginal delivery, 
and EPO levels were determined in cord blood samples. Similarly, in our study on term 
asphyxiated neonates with various delivery modes (III), no correlation of umbilical cord 
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serum EPO with umbilical artery pH occurred, but EPO levels correlated with umbilical artery 
BE. The variation in delivery modes and in sampling methods among these studies may 
explain the difference in findings, since uterine contractions during even normal vaginal birth 
can affect umbilical cord pH and EPO concentrations at birth (246,339). The increased am-
EPO levels and decreased pH and BE values in Study I most probably reflected actual 
intrauterine circumstances caused by chronic fetal hypoxia. 
In our study on apparently low-risk pregnancies (II), as expected, few abnormal am-EPO 
samples were detectable. Furthermore, low umbilical artery and BE values were uncommon. 
These features of the study population probably explain the lack of correlations of amniotic 
fluid and umbilical cord serum EPO with umbilical artery pH and BE levels. Possibly, however, 
increased EPO levels reflect fetal stress, even if they do not correlate with pH (333). Elevated 
EPO levels may occur without decreases in  umbilical cord pH and BE, since these parameters 
can return to normal levels soon after the hypoxic event (336). 
EPO and neonatal outcomes (I-III) 
Study I. Composite adverse neonatal outcome was strongly associated with abnormal am-
EPO values. Adverse outcomes included cerebral complications—intraventricular 
hemorrhage, periventricular leukomalacia, and cerebral infarction—as well as NEC. Our 
findings are, therefore, in line with those of a study demonstrating that asphyxiated infants 
with subsequent neurodevelopmental sequelae such as CP or developmental delay may 
show at birth increased cord plasma EPO levels (274). Furthermore, am-EPO associates with 
other biomarkers reflecting oxidative stress and neuronal injury, ones such as oxidative and 
nitrosative stress biomarkers, as well as protein S100B (382,410). 
Among our study population, all neonates developing NEC had abnormal EPO levels in their 
amniotic fluid, consistent with the fact that asphyxia elevates risk for NEC among neonates 
with growth restriction (411). Generally, growth restriction causes increased neonatal 
prematurity-related morbidity (137). In our study, gestational age at birth was not associated 
with composite adverse neonatal outcome, however. 
The best cut-off value of am-EPO for predicting adverse neonatal outcome was 25.0 IU/L, in 
substantial agreement with the earlier definition of pathologic EPO level (338). 
Study II. In late-term and prolonged pregnancies, adverse perinatal outcomes such as 
decreased umbilical artery pH and BE values, low Apgar score, intrapartum fetal distress, and 
meconium aspiration occur more frequently than in term pregnancies (36,412). We saw only 
a few cases of intrapartum fetal distress, or of neonates with low Apgar score or low umbilical 
artery pH and BE; and our definition of composite adverse outcome was relatively mild. Thus, 
we were unable to demonstrate any association between antenatal am-EPO levels and 
adverse outcomes among these apparently low-risk pregnancies. 
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Study III. Relatively mild asphyxia criteria included neonates with at least two of the 
following criteria: umbilical artery pH < 7.10, umbilical artery BE ≤ 12.0 mmol/L, and/or five-
minute Apgar score < 7. Us-EPO correlated with Apgar score at five minutes; nonetheless, it 
was not higher among the neonates with asphyxia than among the control neonates. This 
may reflect the nature of EPO as less a biomarker of acute asphyxia than of chronic hypoxia. 
Delivery characteristics and EPO (II, III) 
Umbilical cord serum EPO levels differ by mode of delivery, with higher levels following 
vaginal birth than in birth via planned cesarean section (25,339). In Study II, am-EPO levels 
between women who succeeded in vaginal delivery and those who ended with acute 
cesarean section were comparable. Thus, in this low-risk population, am-EPO did not appear 
to predict intrapartum fetal distress. Nor did any difference appear between delivery modes 
in umbilical cord serum EPO levels (II). The explanation is most likely the exposure to delivery 
contractions, as all the deliveries in this study were primarily planned as vaginal, and all the 
neonates experienced varying stress from uterine contractions.  
In Study III, us-EPO levels were higher among neonates born by acute cesarean section than 
by spontaneous or assisted vaginal birth. This may reflect antenatal conditions leading to 
acute cesarean section. However, no difference appeared in cesarean section rates between 
asphyxia and control groups. Furthermore, the total duration of labor or duration of second-
stage labor showed no correlation with EPO levels in umbilical serum in either of the studies, 
suggesting that normal delivery contractions activate EPO synthesis, but do not typically lead 
to an exponential increase in EPO levels. 
Clinical implications and future directions of EPO determination 
Significance of am-EPO assessment in management of IUGR pregnancy (I). Timing the 
delivery in preterm IUGR pregnancies—ergo, finding a balance between risk for stillbirth and 
risk for prematurity—is a major obstetric challenge. Risk for stillbirth is significantly increased 
in IUGR pregnancies (134). In the GRIT study, delay of delivery by a few days led to increased 
stillbirth rates, but the total numbers of perinatal deaths in the immediate-delivery and in 
the delayed-delivery groups were equal (143). Moreover, a trend towards increased 
neurological disability among the immediate-delivery group occurred at 2 years of follow-up 
(144). In our study on IUGR pregnancies, no stillbirths occurred, and total mortality was well 
comparable with rates from other studies on IUGR (143,302). 
Am-EPO assessment in IUGR pregnancies may be an additional method in fetal surveillance 
and in optimizing delivery timing. When noninvasive surveillance methods cannot confirm 
the wellbeing of the fetus, or if uncertainty remains, amniocentesis may be justified to obtain 
additional information. Elevated am-EPO levels can be a warning of emerging problems 
several days before alterations in other parameters, ones such as CTG (338).  
 84 
Delivery may be safely delayed if am-EPO level is not abnormal, but in cases of moderately 
elevated levels, careful monitoring is necessary. In cases of abnormal EPO levels, especially 
when other surveillance methods are non-reassuring, immediate delivery requires 
consideration. Further studies on the association of abnormal EPO levels with long-term 
neurologic outcomes in IUGR are essential. 
Am-EPO and prediction of adverse outcome in prolonged and low-risk pregnancies (II). We 
hypothesized that am-EPO assessment before labor contractions predicts adverse delivery 
outcomes. Among the low-risk study population, however, abnormal EPO levels and adverse 
outcomes were rare, and it was impossible to demonstrate such a predictive value for am-
EPO. Demonstrating such an association would probably have required considerably larger 
populations. We thus concluded that, in predicting delivery outcomes among low-risk 
populations am-EPO assessment may not prove clinically useful.  
Nevertheless, our study demonstrated that EPO levels in amniotic fluid collected vaginally at 
amniotomy are consistent with the levels in samples collected by amniocentesis. This 
observation could be useful in selected high-risk pregnancies, where either am-EPO 
assessment at amniotomy or at spontaneous rupture of membranes could prove predictive 
of the outcomes. In one earlier study, higher EPO levels in amniotic fluid and umbilical cord 
serum have been detectable among those deliveries which ended in an acute cesarean 
section than among spontaneous vaginal births (340). The am-EPO values can prove of value 
in determining delivery mode, since fetuses with abnormal EPO values may not tolerate the 
stress of delivery contractions.  
Furthermore, the correlation between amniotic fluid and umbilical serum EPO levels was 
persistent after vaginal delivery. This information may prove useful in estimating the timing 
of possible hypoxic events among asphyctic neonates and in differentiating chronic from 
acute hypoxia. Further studies on these issues are warranted. 
Umbilical cord serum EPO, and delivery and neonatal outcomes (II, III). In Study II, a 
considerable portion of the population had, at birth, abnormal umbilical cord serum levels, 
and median cord serum EPO level was close to our definition of abnormal EPO level. In most 
of the cases, however, neonatal adverse outcomes were absent. Instead, among the 
neonates born by cesarean section for fetal distress, us-EPO levels were abnormal in all 
cases. This may reflect either fetal response to stressful events during delivery, or antenatal 
conditions contributing to decreased resilience to stress caused by delivery contractions. 
That us-EPO levels were not significantly higher among asphyxiated neonates (III), may be 
explained by the nature of EPO as a marker of chronic hypoxia more than as a marker of 
acute hypoxia (25). Additionally, the relatively mild asphyxia criteria we used may have 
influenced study findings. 
The mechanisms of EPO effects are complex. Association of EPO with neonatal outcomes, 
especially with long-term outcomes, is not fully elucidated as yet. Studies are warranted on 
the long-term neurologic health of children who, during pregnancy and at birth, show 
increased EPO values.   
 85 
UMBILICAL SERUM S100B (III) 
At early stages of acute asphyxia, S100B plasma levels increase (413,414). Among 
asphyxiated neonates, elevated S100B levels are associated with IVH or HIE (379). In a recent 
report on a small case series, elevated cord serum S100B levels were related to cord blood 
acidosis, severity of aEEG pattern abnormalities, HIE stages II and III, and 6-year 
neurodevelopmental health (47). S100B levels have been correlated with gestational age 
(380), but contradictory findings have emerged (47). 
Our study found no correlation of umbilical serum S100B with arterial pH at birth. More 
importantly, a correlation with umbilical artery BE and with Apgar score at 5 and 10 minutes 
occurred. No difference in S100B levels between asphyxiated and unaffected controls 
appeared, however, most probably explained by our relatively mild definition of asphyxia 
and our selection method for our control population. We found no correlation of gestational 
age with S100B levels, as has been reported earlier (19). Furthermore, we failed to confirm 
others’ findings of higher S100B levels among neonates born vaginally (19). What may 
explain this disparity is that our study population included no planned cesarean sections. The 
significance of S100B assessment in umbilical cord serum in predicting asphyxia and HIE thus 
requires further study. 
UMBILICAL SERUM COPEPTIN (III) 
One of the essential adaptation mechanisms at birth is activation of the HPA axis, which 
results in release of AVP from the pituitary. This release is further enhanced by various 
stressors such as infections and hypoxia (51,52,395). AVP is highly unstable, and its secretion 
is measurable by its surrogate peptide copeptin, derived from the same hypothalamic 
precursor molecule and released in concentrations equal to those of AVP (389). Among 
normal births, copeptin levels show a negative correlation with umbilical cord blood pH and 
BE (51). These levels are further increased in birth asphyxia (52). Furthermore, high levels of 
copeptin among preterm neonates at birth are associated with adverse neonatal outcomes 
such as IVH (395). 
Copeptin levels and neonatal outcomes 
Consistent with earlier data, we demonstrated a highly significant correlation of copeptin 
with umbilical artery pH and BE. Its strong correlation with BE—the most important single 
criterion for metabolic acidosis and birth asphyxia (248)—is of special interest. In line with 
this finding, copeptin levels among the asphyxiated neonates were significantly higher than 
levels in unaffected controls. The moderate sensitivity and specificity parameters in the ROC 
analysis in our study, as compared to earlier numbers (52), are related to our inclusion 
criteria of the control group with Apgar score ≥ 4, and rather mild asphyxia criteria. 
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Copeptin levels and delivery characteristics 
Umbilical serum copeptin levels are higher after vaginal delivery than after delivery by 
planned cesarean section (51). Consistently, our study’s copeptin levels were higher among 
neonates born vaginally—spontaneous and assisted vaginal birth numbers combined—than 
among cesarean-section neonates. Copeptin levels, as previously reported, were highest 
among assisted vaginal births (51). The difference between spontaneous vaginal births alone 
and acute cesarean sections was non-significant. This is attributable to the study population 
comprising only neonates who had experienced variable periods of labor contractions before 
being born, either vaginally or by cesarean section.   
Additionally, we demonstrated a correlation of copeptin with duration of labor and with 
duration of the second stage of labor. This finding is in line with recent observations that 
even a few contractions are enough to activate the release of AVP and copeptin, and that its 
half-life of 30 minutes allows copeptin to accumulate during delivery (26,415). The 
accumulating copeptin may also reflect stress of delivery, which is advantageous for 
adaptation at transition within normal limits, but may turn out to be overwhelming if 
continuing for excessively long, as in cases of labor dystocia. 
Clinical implications of copeptin assessment at birth 
According to our findings, copeptin is a highly promising biomarker of neonatal distress and 
asphyxia, having the potential to become part of a routine examination. Serum copeptin 
serves as a diagnostic and prognostic biomarker in certain adult emergency departments 
(49,50). Thus, this assessment could be easily implemented for neonatal intensive care units. 
Recently, a rapid immunoassay for copeptin point-of-care testing became available (398), to 
improve the suitability of copeptin assessment in clinical practice. Future studies are 
warranted on the correlation of copeptin with HIE stage and long-term neurologic outcomes. 
Sequential copeptin evaluations may enhance the prognostic value of this biomarker and 
thus call for further study. Wider clinical utilization of copeptin requires introduction of quick 
assessments and the easy availability of these tests in daily practice. 
COMPARISON OF UMBILICAL SERUM BIOMARKERS (III) 
Our distinct biomarkers have different bases and profiles in perinatal asphyxia (25,51,414). 
AVP—measured by copeptin—plays a central role in neonatal adaptation at birth, protein 
S100B reflects neuronal injury, and EPO is primarily a biomarker of chronic hypoxia. 
Consequently, these variable features mostly explain the differences that appear in our 
study. 
Copeptin turned out to be the only biomarker associating significantly with birth asphyxia. 
We were unable to demonstrate the potency of either S100B or EPO as biomarkers of acute 
birth asphyxia. This may reflect the acuteness of the asphyxia among the study population 
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or may be related to the inclusion criteria and the asphyxia definition that we applied. Our 
definition is, however, supported by the evidence that falling in the tenth centile of umbilical 
artery pH at birth of approximately 7.15, and having a five-minute Apgar score less than 
seven both associate with neonatal morbidity (254,255,406). 
Furthermore, copeptin was the only biomarker which increased as a function of labor 
duration. Thus, our study suggests that, as a predictor of acute birth asphyxia, copeptin is 
the most potential of these three biomarkers.  
ASPHYXIA AND NEUROLOGIC MORBIDITY IN TERM AND POST-TERM PREGNANCIES (IV) 
In many countries, the elective delivery induction rate at early term and after the 41+0 GW 
has increased substantially, leading to a decrease in number of post-term births, and an 
increasing number of early-term births (416). In Finland, such routine inductions have been 
less common, even though induction of delivery is more frequent among early-term and 
postterm pregnancies. During the 20-year study period, the overall delivery-induction rate 
increased (41), but the early-term birth rate remained unchanged, and post-term birth rate 
slightly increased. Furthermore, our perinatal mortality and long-term morbidity numbers 
were comparable with those reported earlier (187,417-419). The controversial association 
of delivery induction with CP (216,217) did not arise here. 
Early morbidity in early-term and postterm pregnancies 
Low Apgar score at 5 and 10 minutes in term deliveries is frequently related to acidosis and 
perinatal asphyxia and predicts increased risk for neonatal morbidity and mortality 
(252,254,420). In earlier studies, long-term neurologic sequelae such as decreased cognitive 
function (421), epilepsy (253,422), and CP (252,253) have been associated with low Apgar 
score. Our strongest risk factor for neurologic morbidity was low Apgar score at one minute. 
This may in part be due to limitations in the MBR data on five-minute Apgar score. 
Nevertheless, this finding is in line with recent cohort-study findings of a strong association 
of one-minute Apgar score with long-term neurologic sequelae (423). Furthermore, low one-
minute Apgar score < 7 predicts CP in moderately and late preterm births, as well (424). 
Consistent with earlier studies, both postterm and early-term birth were associated with 
increased risk for low Apgar score (190,418). 
Low umbilical artery pH at birth associates with increased risk of neurologic morbidity and 
neonatal mortality (249,425). Risk for neonatal encephalopathy increases along with 
deepening acidemia (21). The predictive value of birth acidosis for neurologic sequelae is 
poor, however (245,425). We demonstrated an association of low umbilical artery pH—at 
pH values between 7.00 and 7.10—with long-term neurologic sequelae. Even in low-risk 
pregnancies, along with advancing gestation, umbilical artery pH tends to decrease 
(189,191). Consistent with this, postterm birth was confirmed to rise as an independent risk 
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factor for low umbilical artery pH. In contrast, and in line with earlier reports, early term birth 
was not associated with low umbilical artery pH (426).   
Long-term neurologic morbidity risk factors 
Neurologic complications and developmental abnormalities are assumed to occur 
excessively among children born postterm (189,427). Among term pregnancies, the risk for 
CP appears in a U-shaped pattern, with the highest risk occurring at 37 GW and beyond 42 
weeks (400). However, contradictory reports exist on the association of CP with postterm 
births, with early-term births frequently included in reference groups (400,428). We 
demonstrated the highest risk for CP among births at early term, whereas not confirming 
elevated risk among births at postterm. Similarly, we could not confirm the earlier findings 
of an association of postterm birth with epilepsy (429), whereas early-term birth did 
associate with epilepsy and sensorineural defects. The highest IQ values occur among 
individuals born at term, with lower IQs in early-term and postterm births (193,430). This is 
consistent with our demonstrating elevated risk for intellectual disability among both early-
term and postterm births.  
The fact that emergency cesarean section associates with neurologic morbidity most 
probably reflects the circumstances leading to cesarean section, such as fetal distress during 
delivery. Interestingly, emergency cesarean deliveries were more frequent among early-
term and postterm births than among full-term births. 
Despite its associations with low pH and with low Apgar score, postterm birth did not elevate 
risk for long-term neurologic sequelae, as did early-term birth. This may be explained by 
early-term neonates’ relative physiologic immaturity and increased vulnerability (426). 
Time periods 
The five-year periods in the study revealed some changes in adverse outcomes possibly 
related to changes in clinical management. The incidences of MAS and low one-minute Apgar 
score increased, while incidence of low umbilical artery pH remained stable. The rates of 
early-term and postterm pregnancies remained substantially unchanged during the entire 
study period, and thus cannot explain this. Furthermore, we demonstrated increasing 
incidences of epilepsy, intellectual disability, and sensorineural defects, all of which may 
reflect improved diagnostics and advanced data-collection systems. Overall, our neurologic 
morbidity rates were well comparable to internationally published numbers (253). In 
contrary to earlier reports of an unchanging prevalence of CP worldwide (419), we found a 
tendency of CP numbers to have decreased during the study period in Finland. A similar 
decrease in CP rates was earlier reported in Finland among children born moderately and 
late preterm (424). 
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Clinical implications and future considerations 
Gestational age has an influence on neonatal outcomes, even after completion of gestational 
weeks defined as term pregnancy. Risks for various neonatal complications are increased at 
both extremes of term and postterm birth. 
We observed an association of early-term birth with short-term morbidity and long-term 
neurologic sequelae. These findings are well in line with earlier findings of a relationship of 
neurologic impairments with early-term birth and support the recent recommendations on 
avoiding unnecessary deliveries in early-term gestation (34,183,184). Such 
recommendations do not apply to medical indications for deliveries. Future studies may 
further elucidate the effect of pregnancy complications on neonatal outcomes at early term. 
We confirmed the increased risk for birth asphyxia and for short-term morbidity among 
neonates born postterm, but the impact on long-term neurologic health was less important 
than earlier reports led us to expect (189,427). Intellectual disability was the only neurologic 
outcome associated in our study population with postterm birth. Conceivably, postterm birth 
seems to encompass fewer risks than previously assumed, especially among pregnancies 
receiving inclusive health care. Furthermore, management of pregnancies beyond 41 GW 
affects a high proportion of pregnant women. This emphasizes the need for further studies 
on the optimal management of pregnancies beyond 41 GW (211).  
PERINATAL MORTALITY IN TERM AND POSTTERM PREGNANCIES (IV) 
In the literature, perinatal mortality rates—including both early neonatal deaths at ≤ 7 days 
and stillbirths—rise along with advancing gestations in term pregnancies, from 0.7 cases per 
1000 deliveries at gestational week 37 up to 5.8 at 43 GW (36,187,189,412). Several studies, 
however, describe a U-shaped relationship of gestational age with mortality rates among 
term births (40,190). Some studies have observed the highest risk for perinatal mortality in 
early-term births (187,431), consistent with our findings. In one earlier study, perinatal 
mortality rates were elevated in those countries with a substantial proportion—more than 
4%—of postterm deliveries (39). Our results were in contrast to this, possibly reflecting the 
high quality and availability of the basic health-care system and pregnancy-management 
protocols in Finland. 
In high-resource countries, stillbirth risk estimates range from 1.6 to 5.3 cases per 1000 
deliveries (189,432). The most realistic way to put stillbirth risk into perspective is to 
compare its rate to numbers of pregnancies ongoing at the same gestation (187,431). 
Calculated by such a method, the risk for stillbirth in our study population was lower in early-
term and postterm pregnancies than in full-term pregnancies. This is consistent with some 
findings of no increase in stillbirth numbers beyond postterm (188). 
Total perinatal mortality decreased as expected during the study period, owing mostly to our 
decrease in stillbirth numbers. We observed an increased risk of perinatal mortality among 
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early-term births, but no such risk associated with postterm birth. Considering postterm 
births, our results were in line with those of a recent Finnish study (215). In weighing these 
findings, the low absolute number of perinatal deaths must be considered, as well. 
Additionally, studies on the influence of pregnancy complications on perinatal mortality 
numbers are essential. 
STRENGTHS AND LIMITATIONS OF THE STUDIES 
In our study on IUGR (I), all of the women delivered by cesarean section; thus, delivery mode 
had no effect on umbilical-cord blood parameters. Women with conditions potentially 
altering fetal EPO concentration we excluded. Therefore, we were able to evaluate changes 
in EPO levels related specifically to IUGR. We had limited data on MCA and ductus venosus 
Doppler, owing to our retrospective study design with its long study period. The seven-day 
cut-off from sampling to delivery may underestimate actual EPO levels, since rapid elevations 
in EPO concentrations occur in pathological pregnancies. Our study population comprised 
patients with amniocentesis performed for non-reassuring findings in Doppler parameters 
or in their biophysical profile and may hence not be totally representative of unselected IUGR 
pregnancies. 
The study on term- and postterm pregnancies (II), included only apparently low-risk 
pregnancies.  We were thus able to evaluate the impact of gestational age on EPO levels 
without any possible influence of fetal hypoxia on these levels. However, we cannot totally 
exclude the possible effect of indication for delivery induction on EPO values. The number of 
umbilical cord blood samples that were lacking was considerable, and some selection of 
patients may have occurred. However, the outcomes of the study population and those 
lacking samples were comparable. 
The study on birth asphyxia biomarkers (III) used relatively mild asphyxia criteria, which may 
explain some mitigation of the findings. Data on clinically estimated HIE grade of the 
neonates and the need for resuscitation procedures would have provided valuable additional 
information. Furthermore, the design of the patient recruitment and final study group 
allocation led probably to a less vigorous control group as compared to the standard 
population. 
The small sample size in all the biomarker studies (I, II, and III) caused some limitations. 
Multivariant analyses were not performed in these studies partly because in small 
populations such analyses are not relevant. Power analyses in these studies were also 
lacking. It is challenging to define a sufficient difference with clinical relevance for biomarker 
levels in these study compositions. 
The study on early and postterm births (IV) comprised a large population-based cohort, and 
this allowed evaluation of rare adverse events. The homogenous population in Finland 
during our study period is an additional strength. We recognized the limitations common in 
observational register studies. The registers provided limited data on several factors such as 
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indication of delivery induction, umbilical artery BE values, and five-minute Apgar score. The 
study population also included high-risk pregnancies and infants with congenital anomalies, 
which may have influenced timing of delivery and exaggerated morbidity among early-term 
birth. We included all children at age four years with any diagnosis of palsy; thus, on rare 
occasions children may not have had CP, but other kinds of palsies. During the long study 
period, pregnancy-dating practice changed. This may have led to underestimation of the 
effect of gestational age on CP during the earliest five-year periods, before routine 
ultrasonography dating (400). 
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CONCLUSIONS 
In pregnancies complicated by IUGR before 34 GW, high EPO levels in amniotic fluid were 
associated with decreased umbilical artery pH and BE, and with increased risk for neonatal 
morbidity. We suggest that in selected pregnancies with severe preterm IUGR, am-EPO 
assessment may prove a useful additional tool in fetal monitoring and in optimizing timing 
of delivery. 
Am-EPO levels correlated with gestational age in term- and prolonged pregnancies, and with 
us-EPO, even after delivery contractions. EPO levels were higher in prolonged pregnancies 
than in term pregnancies. In this study, however, am-EPO levels were not related to adverse 
outcomes. Therefore, determining EPO levels in amniotic fluid at induction of labor turned 
out not to be useful in routine practice for predicting delivery outcomes among low-risk 
pregnancies. However, EPO levels in amniotic fluid can be easily and safely determined from 
samples obtained by amniotomy at induction of labor. Further studies on am-EPO 
assessment, either at amniotomy or in spontaneous rupture of membranes, are justifiable in 
selected high-risk pregnancies. In such circumstances, abnormal EPO level could guide 
delivery management with more intensive fetal monitoring, or even influence decisions 
concerning eventual delivery mode. 
Our study on umbilical serum biomarkers indicates that copeptin proved to be a high-
potential biomarker of acute birth asphyxia and neonatal distress and may thus become a 
routinely used assessment among neonates in poor condition at birth. Serum copeptin 
serves as a diagnostic biomarker of suspected myocardial infarction in adult emergency 
departments. Recently, a sensitive and rapid assay for point-of-care testing has emerged, 
that could easily be introduced to neonatal intensive care units, as well. Correlation of 
copeptin levels with severity of HIE and long-term neurologic outcomes calls for further 
study. In this study population, S100B and EPO proved ineffective as biomarkers of acute 
asphyxia. Combined data on fetal Doppler flow parameters and biomarkers also need further 
examination in a prospective study on high-risk pregnancies such as IUGR. 
Neonatal outcomes vary by gestational age at birth. Our study demonstrated that numerous 
complications were increased at both extremes of term and postterm birth. Early-term birth 
between 37+0 and 38+6 GW was associated with low Apgar score, increased long-term 
neurologic morbidity, and perinatal mortality. Among postterm births ≥ 42 GW, asphyxia and 
intellectual disability were more frequent than after full-term birth, but general neurologic 
morbidity and perinatal mortality were not increased. Accordingly, birth in the early-term 
period appears to elevate risks involving long-term neurologic health, whereas birth at 
postterm seems to confer fewer risks than previously assumed. 
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